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Abstract 
Streptococcus salivarius is known to produce different bacteriocin-like inhibitory 
substances (BLIS). In this study six S. salivarius strains were isolated from different 
Malaysian subjects. The isolates were identified using morphological and biochemical 
characterization and 16S rDNA gene sequencing. Levansucrase enzyme was characterized 
from sucrose-enriched culture of strain S. salivarius YU10. 
BLIS production was investigated using simultaneous and deferred antagonism tests that 
showed YU10 and NU10 as the best BLIS-producing strains among the Malaysian isolates 
in this study. Strain HJEFF was the only S. salivarius isolate which produced a more 
limited quantity of BLIS in liquid medium. However, all other strains failed to produce any 
BLIS activity in liquid media. The distribution of salA, sboB and sivA genes encoding the 
production of salivaricin A, B and 9 was investigated in this study using BLIS producing 
strains NU10 and YU10. Strains NU10 and K12 (commercial probiotic) were the only 
strains that harboured the sboB structural gene.  Both strains (NU10 and YU10) but not 
K12 harbored the sivA structural gene. Isolation of BLIS was done using acidic methanol 
extraction of the producer cells and freeze thaw extraction. BLIS-YU10 proved 
bacteriostatic while BLIS-NU10 was bactericidal. When added to different growth phases 
of sensitive bacteria, BLIS-NU10 reduced its growth significantly. BLIS-NU10 was 
purified from its crude form using different steps of initial purification namely ammonium 
sulphate precipitation, gel filtration, XAD-2 and solid phase extraction chromatography.  
BLIS-NU10 showed to be auto-regulated whereby it enhanced the production of the same 
molecule when added to NU10 culture. The induction ability was used to develop BLIS-
production in liquid medium. BLIS-NU10 showed to be of cationic nature and it was 
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purified using a cation exchange column. The cation exchange chromatography was 
performed using Fast Protein Liquid Chromatography system. Tris-ticine SDS page of the 
active fractions showed that BLIS-NU10 had a molecular weight of approximately 3,000 
Da. The pure fraction was subjected to MALDI-TOF MS analysis. The only known 
salivaricin detected in BLIS-NU10 was salivaricin 9 (2560 Da). Other peptides where also 
detected in BLIS-NU10 with molecular weights of approximately 2,000 Da.  
BLIS-NU10 showed to have permeability activity towards selected target cells and showed 
to induce pore formation in the cytoplasmic membrane of targeted cells. The stability of 
BLIS-NU10 was also investigated in this study. BLIS-NU10 exhibited thermo-stability 
when exposed to 100oC for 30 minutes and retained biological activity when subjected to 
different pH values ranging from 2 to10. When treated with proteinase K or peptidase, 
BLIS-NU10 lost the antimicrobial activity. One major difficulty with strain NU10 was its 
erratic BLIS production. However, although strain NU10 harbors three different genes 
encoding known lantibiotics, analysis of pure BLIS-NU10 showed the presence of only 
lantibiotic salivaricin 9 in addition to other proline-rich peptides. The reason for the 
absence of salivaricin A and B in the purified BLIS-NU10 is still unknown and worthy of 
further investigation. Due to its uniqueness, strain NU10 can be further studied using whole 
genome sequencing approach to determine if this strain can be a potential probiotic.   
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Abstrak 
Streptococcus salivarius dikenali untuk menghasilkan bahan-bahan yang melarang 
bakteriosin seperti berbeza (BLIS). Dalam kajian ini enam jenis S. salivarius telah 
diasingkan daripada mata pelajaran yang berbeza di Malaysia. Pencilan telah dikenal pasti 
menggunakan pencirian morfologi dan biokimia dan 16S rDNA urutan gen. Enzim 
Levansucrase dicirikan dari budaya yang kaya dengan sukrosa ketegangan S. salivarius 
YU10. Pengeluaran BLIS telah disiasat menggunakan ujian permusuhan serentak dan 
tertunda yang menunjukkan YU10 dan NU10 sebagai yang terbaik jenis BLIS yang 
menghasilkan antara pencilan Malaysia dalam kajian ini. Terikan HJEFF adalah satu-
satunya S. salivarius mengasingkan yang menghasilkan kuantiti yang lebih terhad BLIS 
dalam medium cecair. Walau bagaimanapun, semua jenis lain gagal mengemukakan apa-
apa aktiviti BLIS dalam media cecair. Pengagihan salA, sboB dan sivA gen pengekodan 
pengeluaran salivaricin A, B dan 9 telah disiasat dalam kajian ini menggunakan BLIS 
menghasilkan tekanan NU10 dan YU10. Terikan NU10 dan K12 (probiotik komersial) 
adalah satu jenis yang melabuhkan gen struktur sboB. Kedua-dua jenis (NU10 dan YU10) 
tetapi tidak K12 menaruh gen sivA struktur. Pengasingan BLIS telah dilakukan dengan 
menggunakan pengeluaran methanol berasid daripada sel sel pengeluar dan pengeluaran 
cair beku. BLIS-YU10 membuktikan bacteriostatic manakala BLIS-NU10 adalah bakteria. 
Apabila dimasukkan ke dalam fasa pertumbuhan yang berbeza bakteria sensitif, BLIS-
NU10 dikurangkan pertumbuhan ketara. BLIS-NU10 telah disucikan dari bentuk mentah 
dengan menggunakan langkah-langkah yang berbeza pembersihan awal iaitu hujan 
ammonium sulfat, penapisan gel, XAD-2 dan pepejal fasa kromatografi pengekstrakan. 
BLIS-NU10 menunjukkan untuk menjadi auto-terkawal di mana ia meningkatkan 
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pengeluaran molekul yang sama apabila ditambah kepada NU10 budaya. Keupayaan 
induksi telah digunakan untuk membangunkan BLIS pengeluaran dalam medium cecair. 
BLIS-NU10 menunjukkan kepada bersifat kationik dan ia telah disucikan menggunakan 
ruang pertukaran kation. Pertukaran kromatografi kation dilakukan menggunakan Protein 
Sistem Kromatografi cecair segera. Tris-ticine SDS halaman pecahan aktif menunjukkan 
bahawa BLIS-NU10 mempunyai berat molekul kira-kira 3,000 Da. Pecahan tulen adalah 
tertakluk kepada MALDI-TOF analisis MS. Salivaricin hanya diketahui dikesan dalam 
BLIS-NU10 adalah salivaricin 9 (2560 Da). Peptida lain di mana juga dikesan dalam BLIS-
NU10 dengan berat molekul kira-kira 2,000 Da. BLIS-NU10 menunjukkan mempunyai 
aktiviti kebolehtelapan terhadap sel-sel sasaran terpilih dan menunjukkan kepada 
mendorong pembentukan liang dalam membran cytoplasmic sel sel yang disasarkan. 
Kestabilan BLIS-NU10 juga diselidiki dalam kajian ini. BLIS-NU10 dipamerkan termo-
kestabilan apabila terdedah kepada 100°C selama 30 minit dan mengekalkan aktiviti 
biologi apabila tertakluk kepada nilai pH yang berbeza antara 2 tersebut adalah 10. Apabila 
dirawat dengan proteinase K atau peptidase, BLIS-NU10 hilang aktiviti antimikrobial. 
Salah satu masalah utama dengan tekanan NU10 adalah pengeluaran BLIS tidak menentu 
itu. Walau bagaimanapun, walaupun ketegangan NU10 pelabuhan tiga gen yang berbeza 
pengekodan lantibiotics dikenali, analisis tulen BLIS-NU10 menunjukkan kehadiran hanya 
lantibiotic salivaricin 9 di samping lain lain peptida proline yang kaya. Sebab ketiadaan 
salivaricin A dan B dalam suci BLIS-NU10 masih tidak diketahui dan memerlukan siasatan 
lanjut. Disebabkan keunikannya, ketegangan NU10 boleh lagi dikaji dengan menggunakan 
pendekatan keseluruhan genom penjujukan untuk menentukan sama ada tekanan ini boleh 
menjadi potensi probiotik. 
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Different genera of lactic acid bacteria (LAB) can produce different kinds of antimicrobial 
peptides and bacteriocins such as plantaricin from Lactobacillus plantarum (Tiwari and 
Srivastava, 2008), enterococcin from Enterococcus faecium (Klocke et al., 2005), leucocin 
from Leuconostoc carnosum (Wan et al., 2012), pediocin from Pediococcus acidilactici 
(Papagianni and Anastasiadou, 2009) and several others. The scientific interest in 
bacteriocins has increased significantly recently due to their antimicrobial activity towards 
Gram-positive pathogens (Abee et al., 1995; Lee et al., 2011; Wilson-Stanford and Smith, 
2011). Bacteriocins produced by many oral microorganisms have been reported previously 
(Hyink et al., 2007; Nicolas et al., 2011; Wescombe et al., 2012; Wescombe et al., 2006; 
Wescombe et al., 2011). Most of the bacteriocins produced by human oral streptococci are 
understood to be controlled by quorum sensing, whereby it can only produce the bioactive 
bacteriocin when grown on solid or semi-solid medium supplemented with agar or agarose 
(Hyink et al., 2007; Nicolas et al., 2011; Ross et al., 1993). Other lantibiotics such as nisin 
could be produced in significant quantity when the producer is grown in liquid medium 
(Flores and Alegre, 2001; Gonzalez-Toledo et al., 2010; Lv et al., 2005). In recent years 
methods to enhance and optimize bacteriocin production have been developed (Cheigh et 
al., 2005; Liu et al., 2010; Pongtharangkul and Demirci, 2006) due to the potential 
importance of bacteriocin-producing strains in replacement therapy (Cotter et al., 2005). 
Many strains produce bacteriocins that have already been used as probiotics. Streptococcus 
salivarius K12 is an oral probiotic producing two kinds of antimicrobial peptides referred 
as salivaricin A2 and salivaricin B (Hyink et al., 2007). Both bacteriocins can be produced 
by freeze thaw extraction method after the producer is grown on solid medium. Pore 
forming mechanism is a common mode of action of lantibiotics (Garcera et al., 1993; van 
Heusden et al., 2002). The permeabilization of the cytoplasmic membrane of the targeted 
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cells by lantibiotics has been studied in the past to investigate whether the bioactive 
lantibiotic can penetrate the cell membrane of the potential pathogens (Chun and Hancock, 
2000; Zendo et al., 2010). 
In this study a number of S. salivarius strains were isolated from the oral cavity of 
Malaysian subjects. Some of the identified strains showed to produce BLIS molecules with 
antimicrobial activity against selected oral pathogens. New techniques to produce BLIS-
NU10 in liquid medium were developed for the first time using Streptococcus salivarius 
strain NU10 isolated from a Malaysian subject. The purification method used to recover 
BLIS-NU10 was planned in this study through the use of XAD-16 chromatography 
followed by cation exchange chromatography. MALDI-TOF MS analysis showed the 
presence of salivaricin 9 lantibiotic in addition to proline-rich peptides. The current 
research work also included an investigation on the mechanism of action of the pure BLIS-
NU10 using SYTOX green and Real-Time PCR system.  
Scanning electron microscopy was used to detect the morphological changes of the targeted 
indicator microorganisms that are sensitive on exposure to BLIS-NU10. Investigating the 
mechanism of action of lantibiotics produced by oral streptococci was carried out with the 
intent of furthering knowledge in future development of new antimicrobials and probiotics 
that might enhance the health of the human oral anatomy and the upper respiratory tract.  
 
  
3 
 
Main objectives of the study: 
 
1- Isolation, identification and characterization of BLIS producing S. salivarius strains 
and their antimicrobial activity using simultaneous and deferred antagonism assays. 
2- Enhanced production, purification and characterization of the antimicrobial peptide 
using different methods. 
3- Investigation of salA, sboB and sivA structural genes distribution among Malaysian 
isolates. 
4- Elucidation of the mechanism of action of BLIS-NU10. 
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2.1 Lactic acid bacteria 
 
Joseph Lister obtained the first pure culture of lactic acid bacteria which was designated as 
Bacterium lactis in 1873. In 1890 the first starter culture to be used for cheese production 
was introduced. Lactic acid bacteria (LAB) were classified according to Orla-Jensen who 
divided the LAB according to morphology into rods (Lactobacillus and Corynebacterium) 
and cocci (all other genera) and this classification system was only at the genus level and 
this first monograph was the first basis in LAB classification (Orla-Jensen, 1919). LAB are 
Gram-positive, oxidase and catalase negative, non-sporulating, non-motile bacteria which 
includes many genera namely: Lactobacillus, Enterococcus, Pediococcus, Lactococcus, 
Oenococcus, Leuconostoc, Streptococcus and others. All these LAB are acid tolerant and 
can produce lactic acid as a major end product. Current taxonomic outline of lactic acid 
bacteria is stated in table 2.1. Next differentiation of LAB genera was introduced according 
to the mode of glucose fermentation under standard conditions (e.g. non limited supply 
with: glucose, amino acids, nucleic acid precursors, vitamins and oxygen limitation) under 
these fermentation characteristics LAB can be divided into two groups: 
I. Homofermentative bacteria. 
II. Heterofermentative bacteria. 
Based on a biochemical perspective, LAB comprise homofermenters (which 
basically yield lactic acid) and heterofermenters (which produce different 
fermentation products e.g. ethanol, acetic acid, carbone dioxide and formic acid) 
(Kleerebezem and Hugenholtz, 2003). LAB use sugars as primary energy sources to 
grow on substrates (de Vos, 1996). Phosphotransferase system (PTS) and ATP-
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binding cassette (ABC) both are basic systems which contribute in the uptake of 
carbohydrates in LAB. In Lactococcus lactis lactose is hydrolyzed after been 
transported by PTS resulting in transformation of the galactose-6p moiety by the 
tagatose pathway, while in Streptococcus thermophilis only glucose moiety of 
lactose is fermented while the galactose moiety is released into the medium 
(Vaughan et al., 2001). LAB can also produce bacteriocins to compete in their 
environments. Most of these bacteriocins are small peptides with antimicrobial 
properties toward bacteria of the same taxonomically related species (Castellano et 
al., 2008). After the advent of genome sequencing genes encoding bacteriocin 
production in LAB were well understood and studied. Clustered genes associated 
with bacteriocin-coding sequences were well studied in 7 different Lactobacillus 
genomes (Makarova and Koonin, 2007). Bacteriocins play a role in cell signaling. 
Bacteriocin producing LAB also confer self-protection by possessing immunity 
mechanisms (Cotter et al., 2005). LAB have plenty of applications which contribute 
to human health like using those species designated as generally recognized as safe 
(GRAS) in the probiotics industry (Burton et al., 2006). 
 
 
  
8 
 
Table 2.1: Current taxonomic outline of lactic acid bacteria (König et al., 2009) 
Phylum Class Order Family Genus 
Fi
rm
ic
ut
es
 
B
ac
ill
i 
La
ct
ob
ac
ill
al
es
 
Lactobacillaceae 
Lactobacillus 
Paralactobacillus 
Pediococcus 
Aerococcaceae 
Aerococcus 
Abiotrophia 
Dolosicoccus 
Eremococcus 
Facklamia 
Globicatella 
Ignavigranum 
Carnobacteriaceae 
Carnobacterium 
Agitococcus 
Alkalibacterium 
Allofustis 
Alloiococcus 
Desemzia 
Dolosigranulum 
Granulicatella 
Isobaculum 
Lactosphaera 
Marinilactibacillus 
Trichococcus 
Enterococcaceae 
Enterococcus 
Atopobacter 
Melissococcus 
Tetragenococcus 
Vagococcus 
Leuconostocaceae 
Leuconostoc 
Oenococcus 
Weissella 
Streptococcaceae 
Streptococcus 
Lactococcus 
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2.2 Streptococcus salivarius and oral cavity health  
 
Streptococcus salivarius is a member of lactic acid bacteria group or family which form an 
important part of the normal flora of the human oral cavity and upper respiratory tract 
(Kang et al., 2006; Sherman et al., 1943). Among all the dominant streptococci of the oral 
cavity S. salivarius is numerically the most significant colonist, especially on the tongue 
(McCarthy et al., 1965). It is also inhabits the oral epithelial surfaces and is one of the first 
microorganisms to be established in the mouths of infants (Carlsson et al., 1970). It has 
been reported that some strains of S. salivarius can produce many bacteriocins, most of 
which are lantibiotics (Birri et al., 2012; Hyink et al., 2007; Ross et al., 1993; Wescombe et 
al., 2006). These bacteriocins or bacteriocin-like inhibitory substances (BLIS) have been 
reported to inhibit some oral pathogens such as Corynebacterium diphtheriae (Bill and 
Washington, 1975), Streptococcus pneumonia (Johanson et al., 1970) and Streptococcus 
pyogenes (Sanders and Sanders, 1982). S. salivarius usually colonize the tongue dorsum 
and can be found in great numbers there (Aas et al., 2005). Because of the bacteriocin 
molecules that some of S. salivarius can produce, the oral cavity will remain healthy and 
protected. The protection comes from the reduction in oral pathogens numbers. S. 
salivarius strain K12, discovered by Professor John Tagg from Otago University, is the first 
oral probiotic which can produce more than one kind of bacteriocin- the lantibiotics 
salivaricin A2 and salivaricin B (Hyink et al., 2007). This protective mouth bacterium can 
prevent sore throats which can lead to rheumatic fever especially in children. BLIS 
produced by S. salivarius had been described previously (Bill and Washington, 1975; Tagg 
et al., 1983). BLIS are extracellular peptides or protein molecules released by some bacteria 
which can kill some closely related bacteria. BLIS-producer bacteria use these substances 
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to compete better in their environment by reducing the numbers of other related bacteria, 
some of which may cause some diseases in the host.  
 
2.3 Bacteriocins: 
 
Reports of antimicrobial molecules produced by either Gram-positive or Gram-negative 
bacteria have increased gradually through the last decade. Usually these antimicrobials are 
called bacteriocins, specially those of protein nature. Proteinaceous antimicrobial 
bacteriocins which have the physiological capability of interfering with the growth of other 
bacteria have taken researchers attention especially after the significant drug-resistant 
reports due to over use of conventional antibiotics. The first bacteriocins to be investigated 
were the colicins produced by different members of the Enterobacteriaceae family (Jack et 
al., 1995).  
 
2.3.1 Bacteriocins from gram negative bacteria 
 
A variety of bacteriocins can be produced by Gram-negative bacteria e.g. klebsin produced 
by Klebsiella pneumoniae, marcescin produced by Serratia marcescens, alveicin produced 
by Hafina alvei and colicin produced by E. coli. On the basis of their size the bacteriocins 
of Gram-negative bacteria can be divided in three groups: 
- colicin-like bacteriocins (25-80 kDa) 
- microcins (<10 kDa) 
- phage tail-like bacteriocins (multimeric peptide assemblies) 
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2.3.1.1 Colicin-like bacteriocins 
 
Colicins are large plasmid-encoded ribosomally-synthesized bacteriocins produced by 
many strains of E. coli. Colicin synthesis repression is controlled by an inducible DNA 
repair system called the SOS response which helps many bacteria to survive under 
circumstances of exposure to DNA damaging agents (Michel, 2005). Colicins have three 
killing domains which form the functional modules which catalyze deleterious changes in 
the targeted cell. The first step of colicin activation is the binding of central domain 
(located within the central region of the colicin molecule) to the specific receptor (Brunden 
et al., 1984). Translocation of the colicin N-terminus across the outer membrane of the 
targeted cell is the second step of colicin activation. This N-terminal domain differs among 
colicins depending on which import system is used (Pilsl and Braun, 1995). The third step 
in the colicin killing mechanism is formation of pores in the cytoplasmic membrane of the 
target cell and this step is carried out by the C-terminal domain. The killing activity of 
some colicins can be caused by nuclease activity which cut up the nucleic material DNA of 
the target cell (Martinez et al., 1983).  
 
2.3.1.2 Microcins 
 
Members of this group of bacteriocins from Gram-negative bacteria are low molecular 
weight peptides which have a similarity to bacteriocins produced by Gram-positive bacteria 
(Jack and Jung, 2000; Moreno et al., 2002). Microcins are non-SOS-inducible peptides 
which inhibit transcription by binding to the DNA-dependent RNA polymerase RNAP (the 
central enzyme of bacterial gene expression) secondary channel. Binding of microcin 
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within this channel blocks nucleotide substrates from entering the enzyme active site 
(Yuzenkova et al., 2002). 
 
2.3.1.3 Phage tail-like bacteriocins 
 
Phage tail-like bacteriocins are rod-like molecules resembling a bacteriophage tail. 
Members of this group are nuclease and protease-resistant rod-like bacteriocins. 
Cytoplasmic membrane depolarization is the mechanism of action of phage tail-like 
bacteriocins toward sensitive cells (Strauch et al., 2003). Pyocins (bacteriocin produced by 
Pseudomonas aeruginosa) are of two types; R2 related to P2 phage and Pyocin F2, similar 
to lamda phage (Nakayama et al., 2000). 
 
2.3.2 Bacteriocins from gram positive bacteria 
 
Bacteriocins are antimicrobial proteins or peptides produced by many genera of bacteria. 
Many microbiologists are now focusing their interest on bacteriocins which can be 
produced by gram positive bacteria, especially LAB, because the number of bacteriocins 
discovered from this group is increasing exponentially every year. LAB is a sub group of 
gram positive bacteria and can produce four classes of bacteriocins: 
Class I: Lanthionine-containing bacteriocins 
Class II: non- modified bacteriocins 
Class III: large bacteriocins 
Class IV: cyclic peptides 
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2.3.2.1 Class I: Lanthionine containing bacteriocins (Lantibiotics) 
 
Lantibiotics are heat-stable, posttranslationally modified, ribosomally synthesized small 
peptides (Al-Mahrous and Upton, 2011; Islam et al., 2012; Perin et al., 2012; Zhao, 2011). 
Unlike other bacteriocins, this group contains some unusual residues e.g., (Lan) 
Lanthionine and (MeLan) β-methellanthionine (Al-Mahrous and Upton, 2011; Bierbaum 
and Sahl, 1993, 2009; Cotter et al., 2005). Prior to cleavage of the leader peptide 
posttranslational modification happens to the propeptide region of the precursor molecule. 
The modifications are the result of the dehydration of serine (Ser) and threonine (Thr) 
residues to 2,3-dehydoalanine (Dha) and (Z)-2,3-dehydrobutyrine (Dhb) while neighboring 
cysteines (Cys) link covalently to Dha and Dhb resulting in formation of (Lan) Lanthionine 
and (MeLan) β-methellanthionine bridges which give lantibiotics their distinctive ring 
structure (Willey and van der Donk, 2007). Then the leader peptide of 23-59 amino acids is 
proteolytically removed to give the lantibiotic in its bioactive form (Xie and van der Donk, 
2004).  
Many factors play roles in lantibiotic activity, while Lan and MeLan (positively charged 
amino acids) interact with the negatively charged phospholipid head group in the 
cytoplasmic membrane of targeted microorganism, other amino acids like cystine, 
didhydrobutyrine and didhydroalanine increase the bio-activity of the peptide (Morris et al., 
1984).  
Lantibiotics can be subdivided into three subclasses (type A, type B and type C) depending 
on their antimicrobial activity and the mechanisms by which the peptide gains maturity. 
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2.3.2.1.1 Type A lantibiotics  
 
These lantibiotics are screw-shaped and amphipathic molecules with molecular masses 
varying from 2164 to 3488 Da, with 2 to 7 net positive charges. Nisin produced by 
Lactococcus lactis is an example of Type A lantibiotics. Genes encoding nisin production 
are located in a 70 kb conjugative transposon (Rodriguez and Dodd, 1996). Nisin has long 
been used in food preservation (Delves-Broughton et al., 1996; Pajohi et al., 2011; 
Udompijitkul et al., 2012). Nisin production is affected by posttranslational modification of 
a propeptide molecule (Bierbaum and Sahl, 1993; Sahl et al., 1995; Xie and van der Donk, 
2004) before a subtilisin-like protease (encoded by NisP) removes the leader peptide to 
give the nisin bioactive form. The same gene has been found in other lantibiotics (Schnell 
et al., 1992; Siezen et al., 1995; van der Meer et al., 1993; Ye et al., 1995). The first stage 
of the nisin killing activity is an electrostatic interaction between the positively charged C-
terminal residues of nisin and the negatively charged membrane phospholipid of the 
targeted bacteria. After nisin insertion membrane pores are formed and this leads to cell 
death (Breukink et al., 1997). Type A lantibiotics have bacteriocidal activity against gram 
positive bacteria, but not against gram negative bacteria unless the integrity of the outer 
membrane is first disrupted (Blackburn, 1989). S. salivarius can also produce type A 
lantibiotics which are called salivaricins. Hyink et al. (2007) reported that S. salivarius 
strain K12 can produce two different kinds of bacteriocins (salivaricins A & B) both having 
strong inhibitory activity against Streptococcus pyogenes (oral pathogen causes rheumatic 
fever). However, S. salivarius strain 5M6C has been reported to produce a trypsin resistant 
lantibiotic (salivaricin D) which is effective against Bacillus subtilis, Clostridium 
bifermentans and Clostridium butyricum (Birri et al., 2012). Salivaricin 9 (lantibiotic 
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produced by probiotic S. salivarius M18 can inhibit all Streptococcus pyogenes strains 
tested so far) has been described by Wescombe et al. (2011). Usually the genes encoding 
salivaricin production could be located on a megaplasmid (for example, the genes encoding 
salivaricin A & B (Wescombe et al., 2006), or the gene locus can be a DNA chromosomal 
segment like salivaricin D (Birri et al., 2012). However, the genetic locus of salivaricin 9 
can be located on either the chromosome or megaplasmid. The production of salivaricin is 
also dependent on the strain itself, with some strains producing the BLIS in liquid media 
others failing. Strain 5M6C produces salivaricin D when it is grown in MRS broth, but 
strain K12 does not because no detectable activity can be recovered from this strain in 
liquid media. Other ways of obtaining salivaricin from this strain are from cultures on solid 
media (freeze thaw of agar cultures) or methanol extraction of the cells (Wescombe et al., 
2006). Salivaricin 9 produced by strain M18 can be detected by freeze thaw extraction of 
the agar cultures or in liquid media if an inducer of the bacteriocin is added to the liquid 
culture. Some bacteriocins are cell-associated, like SA-FF22 from Streptococcus pyogenes, 
and mutacin K8 produced by Streptococcus mutans (Robson et al., 2007). 
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Figure 2.1: Predicted dehydration/bonding pattern of salivaricin B (Hyink et al., 2007). 
 
 
 
 
 
 
 
 
Figure 2.2: Arrangement of the two gene clusters encoding salivaricins A and B in S. 
salivarius K12 (Hyink et al., 2007).Predicted transcriptional terminators for both loci are 
indicated by stem-loop symbols, with the dashed stem-loop showing a possible weak 
terminator. Two putative genes are located between the two lantibiotic loci. The three 
repeat regions (R1, R2, and R3) identified are also indicated, as is the position of a small 
insertion sequence (IS; black triangle) identified upstream of the salivaricin B locus in 
some strains. 
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 Figure 2.3: Nisin, an example of type A bacteriocins 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Post translation modifications during nisin biosynthesis (Xie and van der Donk, 
2004) 
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2.3.2.1.2 Type B lantibiotics  
 
There are some structural modifications between this subclass and type A lantibiotics. The 
molecular mass of known type B lantibiotics is 1959 to 2041 Da with zero or negative net 
charge (Altena et al., 2000). Mersacidin produced by Bacillus spp is an example of type B 
lantibiotics which contains three ring-form structures of MeLan and a compact size of 20 
amino acids (Herzner et al., 2011).  The mechanism of action of type B lantibiotics is not 
cytoplasmic membrane pore formation, but inhibition of cell wall synthesis by targeting the 
cell wall precursor lipid II (Brotz et al., 1995; Sass et al., 2008). Merasacidin is active 
against methicillin-resistant Staphylococcus aureus (MRSA) and it can be used as a 
potential alternative to vancomycin. 
 
 
 
 
 
 
 
Figure 2.5: Merasacidin, an example of type B lantibiotics 
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2.3.2.1.3 Type C lantibiotics: 
 
Type C lantibiotics basically consist of two peptides working synergistically in a sequential 
pathway with pore forming activity of the cytoplasmic membrane of the targeted cells. 
Lacticin 3147 is an example of this subclass of lantibiotics which consists of two peptides: 
Ltnα, which has a similar structure to type B lantibiotics and Ltnβ which is similar to type 
A lantibiotics in adopting an elongated linear conformation (Martin et al., 2004). The 
activity starts when Ltnα binds to lipid II, followed by interaction of Ltnβ with the Ltnα-
lipid II complex, which results in more peptide insertion and pore formation (Morgan et al., 
2005). 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.6: Lacticin 3147, an example of type C lantibiotics 
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Table 2.2: Lantibiotics produced by lactic acid bacteria 
Lantibiotic  Producing LAB Reference 
Nisin A Lactococcus lactis  (Gross and Morell, 1971) 
Nisin Z Lactococcus lactis  (Mulders et al., 1991) 
Nisin F Lactococcus lactis  (de Kwaadsteniet et al., 2008) 
Nisin U Lactococcus lactis  (Wirawan et al., 2006) 
Nisin U2 Lactococcus lactis  (Wirawan et al., 2006) 
Nisin Q Lactococcus lactis  (Zendo et al., 2003) 
Mutacin B-NY266 Streptococcus mutans  (Mota-Meira et al., 1997) 
Mutacin 1140 Streptococcus mutans  (Hillman et al., 1998) 
Mutacin I Streptococcus mutans  (Tsang et al., 2005) 
Mutacin K8 Streptococcus mutans  (Robson et al., 2007) 
Mutacin II Streptococcus mutans  (Chikindas et al., 1995) 
Streptin Streptococcus pyogenes (Wescombe and Tagg, 2003) 
Macedocin  Streptococcus macedonicus (Georgalaki et al., 2002) 
Lacticin 481 Lactococcus lactis  (Piard et al., 1993) 
Streptococcin A-FF22 Streptococcus pyogenes (Tagg and Wannamaker, 1978) 
Salivaricin A1 Streptococcus salivarius  (Wescombe et al., 2006) 
Salivaricin A2 Streptococcus salivarius  (Wescombe et al., 2006) 
Salivaricin A3 Streptococcus salivarius  (Wescombe et al., 2006) 
Salivaricin A4 Streptococcus salivarius  (Wescombe et al., 2006) 
Salivaricin A5 Streptococcus salivarius  (Wescombe et al., 2006) 
Salivaricin  A Streptococcus salivarius  (Ross et al., 1993) 
Salivaricin B Streptococcus salivarius  (Hyink et al., 2007) 
Salivaricin 9 Streptococcus salivarius  (Wescombe et al., 2011) 
Plantaricin C  Lactobacillus plantarum  (Turner et al., 1999) 
Plantaricin W Lactobacillus plantarum  (Holo et al., 2001) 
Lacticin 481 Lactococcus lactis  (Piard et al., 1993) 
Lacticin 3147 Lactococcus lactis  (McAuliffe et al., 1998) 
Lacticin J46  Lactococcus lactis  (Huot et al., 1996) 
SmbB  Streptococcus mutans (Yonezawa and Kuramitsu, 2005) 
BhtA Streptococcus rattus (Hyink et al., 2005) 
Lactocin S Lactobacillus sake (Mortvedt et al., 1991) 
Bovicin HJ50 Streptococcus bovis (Xiao et al., 2004) 
Bovicin HC5 Streptococcus bovis (Mantovani et al., 2002) 
Cytolysin  Enterococcus faecalis  (Gilmore et al., 1996) 
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Figure 2.7: Some of bacteriocins types produced by different 
microorganisms http://bactibase.pfba-lab-tun.org. (Hammami et al., 2010). 
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2.3.2.2  Class II: Non- modified bacteriocins 
 
This group of bacteriocins can be divided into three subclasses: 
Subclass IIa: Pediocin-like bacteriocins 
Subclass IIb: Two peptide bacteriocins 
Subclass IIc: Other peptide bacteriocins 
 
2.3.2.2.1 Subclass IIa 
 
The pediocin-like antimicrobial peptides are typical single functional peptides of the class 
II bacteriocins and usually include two cysteine residues that form a disulfide bridge 
(Eijsink et al., 1998). Class IIa bacteriocins can be produced by many LAB, namely 
Pediococcus, Enterococcus, Carnobacterium and Lactobacillus. Pediocin-like peptides 
contain a YGNGV amino acid sequence in their N-terminus. Many studies suggested that 
the C-terminal of pediocin-like peptides play a significant role in their inhibitory activity 
spectrum (Fimland et al., 1996). The mode of action of pediocin-like peptides is similar to 
type A lantibiotics and includes binding, insertion and pore formation in the cytoplasmic 
membrane of the targeted bacterial cell. The hinge motifs between the N-terminal and the 
C-terminal regions play a role in pediocin-like peptide penetration into the targeted 
membrane (Fimland et al., 2005). 
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2.3.2.2.2 Subclass IIb  
The complementary activity of two peptides is the basic characteristic of this kind of 
bacteriocin (Nissen-Meyer et al., 1992). Sometimes the individual peptide cannot be active 
alone but clear synergistic activity is observed upon combination of the two peptides 
(Anderssen et al., 1998). 
2.3.2.2.3 Subclass IIc 
This group of bacteriocins does not contain any of lantibiotics or subclass IIa and IIb 
bacteriocins but represents bacteriocins derived from a variety of LAB. These bacteriocins 
are non-cyclic and non-lantibiotic small peptides. The activity of this group of bacteriocin 
is due to either single or multiple bioactive peptides. 
 
 
 
 
 
Figure 2.8: Pediocin example of Class II (unmodified bacteriocins) 
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2.3.2.3 Class III large bacteriocins 
 
Members of this group are large >10 kDa, heat labile bacteriocins produced mostly by 
streptococcal bacteria. Zoocin produced by Streptococcus equi. subsp zooepidemicus is an 
example of this kind of bacteriocin. Zoocin is 27.8 kDa, antimicrobial peptide with 
similarity to lysostaphin (Simmonds et al., 1997). The mechanism of action of zoocin can 
be summarized by binding to the putative receptor-recognition region of the targeted cell by 
the C-terminal domain of zoocin, while the N-terminal domain is involved in the peptidase 
activity of the molecule which targets the interpeptide crossbridge, which leads to cell wall 
hydrolysis. Dysgalacticin (21.5 kDa anionic protein produced by Streptococcus 
dysgalactiae subsp. equisimilis) is also a member of this group of bacteriocins and it differs 
from zoocin in the mode of action in that dysgalacticin kills its target without inducing 
lysis. Dysgalacticin inhibits sugar uptake into the sensitive cell which leads to loss of 
intracellular potassium ions and disruption of membrane integrity (Heng et al., 2006; Swe 
et al., 2009). 
 
2.3.2.4 Class IV: Cyclic peptides 
 
This group comprises the post translationally modified cyclic peptides whose first and last 
amino acids are covalently joined forming a head-to-tail linkage (Maqueda et al., 2004). 
Enterocin AS-48 produced by Enterococcus faecalis subsp. liquefaciens is a member of this 
group. In enterocin AS-48 there is a peptide linkage between C-terminal Try-70 and N-
terminal Met-1with no thioether residues in the structure. This bacteriocin is heat and pH 
stable (Maqueda et al., 2004). Enterocin can be used in food preservation due to its 
effectiveness at inhibiting Bacillus coagulans and enhancing anti-spore activity when 
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combined with high temperature thermal treatment (Lucas et al., 2006). Uberolysin 
produced by Streptococcus uberis is a 7048 Da cyclic peptide which induces lysis of the 
metabolically susceptible targeted cell. Uberolysin is post-translationally and covalently 
modified to form a head-to-tail monocycle (Wirawan et al., 2007). 
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3.1 Streptococcus salivarius isolates and indicator strains: 
 
The Streptococcus salivarius strains used in this study were strains HJEFF originally 
isolated and maintained in the culture collection of Koshy Philip (Fermentation Laboratory, 
Microbiology Division, Institute of Biological Sciences, University of Malaya), NU10, 
GT2, YU10, IND9 (isolated from healthy Malaysian subjects), SAM3, 7YE (isolated in the 
Dental Clinic of University of Malaya from Malaysian subjects with dental problems) and 
K12™ (producer of salivaricin A2 and salivaricin B) provided by John Tagg (University of 
Otago, New Zealand). S. salivarius strain ATCC13419 (BLIS-negative strain) was used as 
a reference strain. The indicator test strains (Table 3.1) were from the culture collection 
maintained in the Fermentation Laboratory, Microbiology Division, Institute of Biological 
Sciences, University of Malaya and American Type Culture Collection (ATCC). 
Table 3.1: Indicators strains 
Microorganisms Strains 
Actinomyces naeslundii TG2 
Bacillus cereus ATCC14579 
Corynebacterium spp GH17 
Gemella sanguinis TGH12 
Haemophilus parainfluenzae TONEJ11 
Lactococcus lactis ATCC11454 
Micrococcus luteus ATCC10240 
Staphylococcus aureus RF122 
Streptococcus equisimilis ATCC12388 
Streptococcus gordonii ST2 
Streptococcus mutans GEJ11 
Streptococcus pyogenes ATCC12344 
Streptococcus pyogenes ATCC12384 
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3.2 Bacterial growth media and cultures  
 
Difco Mitis Salivarius Agar (MSA) was used to obtain pure colonies of S. salivarius since 
it is a selective medium used for the isolation of S. salivarius, Streptococcus mitis and 
enterococci. Todd Hewitt Broth (THB) was used to propagate all S. salivarius isolates and 
indicator strains. Difco Columbia Agar Base (CAB) was used for antimicrobial activity 
assays (well diffusion and spot-on-lawn). Difco Columbia Agar Base supplemented with 
0.1% (w/v) calcium carbonate and 5% (v/v) whole human blood (BACa) was used in 
simultaneous and deferred antagonism assays. Difco Tryptic Soy Broth supplemented with 
1% (w/v) yeast extract, 0.1% (w/v) calcium carbonate (TSYECa) was also used in deferred 
antagonism tests. Difco M17 Broth supplemented with 1% sucrose and 0.1% calcium 
carbonate M17SUCa was used to produce BLIS activity in strains K12, YU10 and NU10.  
 
3.3 Sterilization and storage conditions 
 
All the liquid media used in this study were steam autoclaved at 121oC for 15 minutes and 
cooled to 30oC prior to use. Agar media was also prepared in the same way as the liquid 
media but they were cooled to 50oC in water bath prior to pouring into petri dishes (20 ml 
each plate). After the agar had set, the plates were inverted and incubated overnight at 37oC 
to ensure its contamination free condition before bacterial inoculation. Both liquid and agar 
media were stored at 4oC for subsequent use.  
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3.3.1 Ultra violet (UV) sterilization 
 
The unopened agar plate and surface was sterilized by exposing to UV light source (270 
nm) for 25 minutes in a covered hood. Tips, pipettes, inoculation loops and all items used 
for bacterial sub-culture and inoculation were sterilized the same way prior to use.  
 
3.3.2 Chloroform sterilization  
 
The agar surface was inverted over a Whatman filter paper no 1 (soaked with chloroform) 
for 30 minutes before the agar surface was aired for another 30 minutes to evaporate any 
residue of chloroform left over. This sterilization technique was used specially for the 
deferred antagonism assay. 
 
3.4 Isolation and identification of Streptococcus salivarius 
 
Streptococcus salivarius strains were isolated from Malaysian subjects using sterilized 
cotton swabs, either from the dorsal surface of the tongue or from saliva. Each subject who 
agreed to participate in this study was required to sign a consent form for isolation of S. 
salivarius from their oral cavity. All protocols used were based on Good Laboratory 
Practices and isolation from subjects conducted with the necessary approval of the 
University Ethics Committee and complied with the principles of the Helsinki Declaration. 
The cotton swabs were kept in 0.85% NaCl before streaking on MSA plates within 1 hour 
of isolation. The plates were incubated anaerobically for 18 h at 37oC and dome shaped 
blue colonies were selected and subsequently sub-cultured on fresh MSA (commonly used 
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for the detection of oral streptococci in human and animals) (Takada et al., 2006). Glycerol 
stocks of the pure cultures were kept at -20oC. Some of the S. salivarius isolates have rough 
shaped colony morphology which can adhere to the agar medium like strain GT2, while the 
others appeared smooth. Gram staining, catalase and oxidase tests  were applied before 
using 50 CHL and 20 Strep API kits  (Biomerieux) to identify the biochemical 
characteristics of the isolates and the final bacteria identification was done using 16S rDNA 
gene sequencing.  DNA was extracted using i-genomic mini kit from iNtRON 
Biotechnology, Korea, with some modifications. The bacterial pellets were washed thrice 
with NaCl 85% to reduce the amount of proteins attached to the cell wall and then 
incubated 10 hours with lysozyme (50 mg ml-1) at 37oC during the lysis step. Universal 
primers 27f (AGAGTTTGATCATGGCTCAG) and 1492r 
(TACGGCTACCTTGTTACGACTT) were used to amplify the 16S rDNA gene. The 16S 
rDNA gene sequence of the samples was compared to the human oral microbiome 
Database BLAST tool.  
For further investigation of the morphology of the isolates, transmission electron 
microscopy TEM was applied to visualize and determine the morphology and size of S. 
salivarius cells and how they replicated to form the typical chaining arrangements. 
Levansucrase enzyme was detected in the cell-free supernatant of strain YU10 as follows; 
M17 medium supplemented with 20% sucrose was used to produce the enzyme from strain 
YU10 after 18 hours of incubation aerobically at 37oC. The sample was subjected to LC-
MS/MS analysis (Thermo Fisher Scientific, UVic Genome BC PROTIOMICS CENTRE) 
and the raw data were analysed with Proteome Discoverer 1.3.0.339 software suite 
(Thermo Scientific).   
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 3.5 Simultaneous antagonism test 
  
A sterilized toothpick was used to pick colonies of S. salivarius grown on MSA and 
stabbed into a fresh lawn of Corynebacterium spp GH17 or Micrococcus luteus 
ATCC10240 seeded on blood agar supplemented with 0.1% CaCO3. This assay was done 
in duplicate plates which were then incubated aerobically at 37oC for 18 hours. A clear 
zone of inhibition surrounding the site where the producer was stabbed was recorded as 
positive bacteriocin-like activity. S. salivarius K12™ (BLIS Technologies) was used as a 
positive control in this study (Figures 4.13 and 4.14) 
 
3.6 Deferred antagonism test  
 
The deferred antagonism test described previously (Tagg and Bannister, 1979) was used 
with minimum modification. The producer strains were streaked across Tryptic Soy agar 
plates supplemented with 1% yeast extract and 0.1% calcium carbonate (TSYECa) or 
BACa plates as a 1 cm wide strip using a sterilized cotton swab. Then the plates were 
incubated anaerobically at 37oC for 20 hours. Then the visible growth of the producer strain 
was removed by using a glass slide and then the agar surface was sterilized by exposing to 
chloroform vapors by inverting the plate over a filter paper soaked with chloroform for 30 
min to kill any living but invisible bacterial cells. The plates were aired for 30 min to 
remove any chloroform residue. Two colonies of the indicator strains already grown on 
CAB (Columbia agar base) were suspended in 3 ml of 0.85% NaCl. Then a cotton swab 
was immersed in this suspension and streaked across the agar plate at a right angles to the 
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producer streak. The plates were again incubated aerobically for 18 hours at 37oC. Zones of 
growth inhibition indicated the presence of inhibitory substances produced by the producer 
strain. Results were recorded as follows: + inhibition zone < 0.75 cm, ++ inhibition zone = 
0.75 - 1 cm, +++ inhibition zone > 1 cm, - no inhibition. 
 
3.7 Distribution of salA, sboB and sivA structural genes in S. salivarius isolates 
 
Primers to detect salA, sboB and sivA (Table 4) were synthesized according to Wescombe 
et al., 2006 and Wescombe et al., 2011). The PCR reactions included 30 cycles that 
included denaturation at 95oC for 30 s, annealing at 55 (salA and sivA) or 44oC (sboB) for 
30 s and finally extension at 65oC for 30 s. The final PCR mixture volume was maintained 
at 50 µl for each single reaction and consisted of 41.5 µl of ultrapure DNA-free water, 5 µl 
of 10X buffer (i-genomic, Korea), 1 µl of dNTP (i-genomic, Korea), 1 µl of each forward 
and reverse primer (10 pmol ml-1) and 0.5 µl of i-Taq (5 U ml-1) (i-genomic, Korea). 
 
Table 3.2: Primers used to detect the genes encoding peptide (salivaricin A, B and 9) 
Lantibiotic Primer 
name 
Primer sequence Reference 
SalivaricinA salAUS GTAGAAAATATTTACTACATACT (Ross et al., 
1993) salADS GTTAAAGTATTCGTAAAACTGATG 
SalivaricinB salBF GTGAATTCTCTTCAAGAATTGACTCTT (Hyink et al., 
2007) salBR AAAATATTCATACCGCTCTTCC 
Salivaricin9 sivF AAAAAGGCGCTTCTATATCCATGA (Wescombe et 
al., 2011) sivR ATCTTTACCTCAAACTTTTAAGTCCATT 
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3.8 Evaluation of inhibitory activity 
 
3.8.1 Production of inhibitory activity in liquid media 
 
All S. salivarius strains failed to express detectable amount of inhibitory substances in 
liquid media, except strain HJEFF which yielded a very small quantity of inhibitory activity 
while growing in Mueller Hinton broth (MHB). Growth experiments were performed in a 
2-litre fermenter (BRAUN BIOTECH INTERNATIONAL) using 2 litre of MHB or THB. 
S. salivarius [4.8 x 104colony forming units (CFU) ml-1] was inoculated and the culture was 
incubated at 37oC for 41 h. Cell viability was determined by the plate dilution method using 
MSA. After enumerating the CFU every hour to determine the growth patterns of S. 
salivarius early stationary phase the cells were collected for BLIS extraction. The cells 
were sedimented by centrifugation 11,000 x g for 5 min followed by filtration of the 
supernatant using a Millipore filter (0.22 µm pore size). Then ammonium sulphate was 
added to attain 50% saturation. After stirring and centrifugation (15,000 x g for 20 min at 
4oC), the precipitate was collected and then dissolved in a minimal volume of phosphate 
buffer saline (PBS) made up to pH 7.0. The crude bacteriocin preparation was desalted by 
using 3,000 Da cut-off dialysis centrifuge tube and then tested for inhibitory activity. 
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3.8.1.1 Binding of BLIS produced by strain HJEFF to DEAE anion exchanger column  
 
Desalted crude peptide produced by strain HJEFF was manually injected onto a DEAE 
anion exchanger column equilibrated in Buffer A (20 mM Tris, pH 8.0) at a flow rate of 
1ml min-1.  
Table 3.3: Column and buffers used in anion exchange study. 
Column* Buffer A Buffer B 
DEAE FF (1 ml) 20 mM Tris, pH 8.0 20 mM Tris, pH 8.0 + 1 M NaCl 
*HiTrap DEAE FF diethylaminoethyl Sepharose, fast flow (weak anion exchanger).  
The column was then washed with 10 ml of buffer A and the effluent was designated as the 
“unbound” fraction. Fractions containing the inhibitory activity started to elute from the 
column following application of buffer B. Each fraction was tested for inhibitory activity 
by the spot-on-lawn method using Corynebacterium spp as the indicator strain.  
 
3.8.2 Acidic methanol extraction 
 
This method was as described by Wescombe et al. (2006) as a standard procedure for 
recovery of Sal-A like peptides, with little modification. One liter of THB base 
supplemented with 0.1% (w/v) calcium carbonate was inoculated with S. salivarius. The 
fermentation process was done by using a BRAUN BIOTECH INTERNATIONAL 
fermenter at 32OC for 18 h. The initial preparation of the BLIS was obtained by extracting 
the cells obtained from the fermentation process mentioned above with 200 ml of 95% 
methanol (adjusted to approximately pH 2 by adding 25 mmol l-1 of HCl) at 4oC for 20 h. 
After centrifugation (15000 x g), the supernatant was subjected to rotary evaporation to 
36 
 
remove the methanol. The extract was then lyophilized and re-dissolved in 1 ml of PBS 
buffer (pH 7). This preparation was used in antimicrobial assay (well-diffusion) to check 
for inhibitory activity. 
 
3.8.3 Freeze thaw extraction 
 
It was noticed that when the producer strain, S. salivarius NU10, is grown in the presence 
of a small quantity of its own bacteriocin product large quantities of bacteriocin are 
produced. A newly modified medium was used in this production experiment that included 
M17 broth supplemented with 1% sucrose, 0.1% calcium carbonate, 0.1 fetal calf serum 
(Sigma) and 0.7% agarose. After the media was autoclaved and cooled down to 50oC, 0.05 
g mL-1 of crude NU10 peptide (4 AU/ml) and 1% of an 18-hour old S. salivarius NU10 
culture grown in THB were added to the production medium prior to pouring it into petri 
dishes (20 ml per dish). After the agarose was set, the plates were incubated anaerobically 
at 37oC for 22 hour before they were transferred to -80oC freezer and kept there for 10 
hours. Then the plates were taken out of the freezer and thawed at room temperature where 
all the plates’ contents (liquid and agarose) were transferred to sterilized gauze to separate 
the agarose debris. The liquid was collected in sterilized Scott bottle. After the cells were 
removed by centrifugation at 12000 x g for 20 min at 4 ºC, the supernatant was collected 
and stored at 4ºC for further purification. 
 
  
37 
 
3.9 Purification of BLIS produced by Streptococcus salivarius NU10 
    
After isolation of the bacteriocin by freeze thaw extraction, solid ammonium sulphate was 
added to the crude peptide to achieve 65% saturation before the solution was stirred 
overnight at 4oC to dissolve the ammonium sulphate. The peptide pellet was collected after 
centrifugation at 18000 x g for 25 minutes at 4oC and the peptide was dissolved in a 
minimal volume of 25 mM phosphate buffer pH 5.8.  This preparation was desalted on 
SEPHADEX G 25 column (sigma) (Column volume 100 ml and diameter 1.5 cm). The 
column was washed with twice the column volume of 25 mM phosphate buffer pH 5.8 
before the sample of 5ml was loaded at a flow rate of 3ml min-1. Protein concentration of 
the fractions was measured using Nanodrop 2000 at 280 nm (Figure 4.22). All the fractions 
were tested for bacteriocin activity by loading 50µl of each fraction into pre-cut wells on 
CAB freshly seeded with Micrococcus luteus ATCC® 10240. Fractions showing 
antimicrobial activity were pooled and lyophilized for storage purpose. The lyophilized 
fraction was dissolved in distilled water and transferred to a shaker flask with 20 g of 
Amberlite® XAD-2 resin added. The mixture was incubated at 4oC for 2 hours on 150 rpm 
orbital shaker. The matrix was packed into glass chromatography column and washed with 
200 ml of distilled water, 200 ml 70% methanol and 200 ml 95% methanol at pH 2. 
Fractions were collected at a flow rate of 5 ml/min. The methanol was evaporated and the 
pellet was dissolved in ultrapure water and filtered by 0.2 nm millipore membrane before 
injecting into Sep-Pack C18 classic cartridge (Waters Model). The cartridge was washed 
with 10 ml of 95% methanol at pH 2 followed by 10 ml ultrapure water before the sample 
was loaded. To elute the activity, 2 ml of different concentrations of methanol were used as 
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follows: 50%, 60%, 70%, 80% and 95% adjusted to pH 2. The fractions were subjected to 
speed vacuum to evaporate the methanol before antimicrobial activity was tested. 
 
3.10 BLIS-NU10 induction assay 
 
BLIS-NU10 production was shown to be auto regulated in this study whereby a small 
amount of the active peptide could induce its production in a large scale production system. 
One colony of an 18-hour old culture of S. salivarius NU10 grown anaerobically on BACa 
agar was used to inoculate 10 ml of M17YESUCa broth and incubated again under the 
same conditions before the cells were collected by centrifugation and washed 3 times in 
saline buffer to reduce the amount of BLIS-NU10 attached to the cells. Two tubes 
containing 0.9 ml of M17YESUCa were inoculated with 0.1 ml of the cell suspension. 0.05 
ml of BLIS-NU10 preparation (titre 4 AU/ml) was added to one of the tubes marked as 
“induced” and the other marked as “control”. Both tubes were incubated anaerobically for 
18 h before 0.05 ml BLIS-NU10 preparation (titre 4 AU/ml) was added to the control tube. 
50µl of each sample (induced and control) was used to test for antimicrobial activity by 
well diffusion assay. The positive control was recorded as a clear zone of inhibition 
representing the induced sample and the inhibition representing the control sample 
appeared nil or faint (Table 4.9).  
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3.11 Production of BLIS-NU10 in liquid medium 
 
Usually bacteriocins produced by S. salivarius can be isolated from cultures grown on solid 
medium using the freeze thaw method described previously (Hyink et al., 2007). Strain 
NU10 is also able to produce the bioactive peptide in solid phase medium and showed 
extremely weak expression of BLIS-NU10 in the liquid media. To overcome this 
limitation, a new technique was used in this study to enhance the production of the BLIS-
NU10 in liquid media. Strain NU10 was grown on MSA plate for 18 h under anaerobic 
condition at 37oC before one colony (dome-shape) was used to inoculate 20 ml of 
M17YESUCa broth and incubated under the same conditions mentioned above on an 
orbital shaker at 150 rpm. The broth culture was centrifuged at 6000 x g for 5 min at 4oC 
before the cells were collected and washed twice in 0.85% NaCl sterile solution and then 
resuspended in 20 ml of the same solution. The cell suspension was used to inoculate 50 ml 
of fresh M17YESUCa broth at 37oC in anaerobic condition for 20 h. The resulting culture 
was fed with fresh 50 ml of the same medium and 0.05 g/ml of pure BLIS-NU10 was 
added to the broth medium as an inducer before the 100 ml culture was incubated for 
another 18 h. 80 ml of the final culture was used to inoculate 1.5 litres of M17YESUCa 
broth. The pH was adjusted to 6.5 using concentrated HCl. CFU and AU was measured for 
colony forming units and arbitrary units per ml during production (Figure 4.31). 
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3.12 Cation exchange chromatography  
 
Induced culture of S. salivarius NU10 was centrifuged at 8000 x g to pellet the cells. The 
cell free supernatant (CFS) was filtered through 0.2 µm sterilized cellulose membrane 
(Millipore). The filtered crude bacteriocin (800 ml) was passed through 100 ml XAD-16 
particles (Sigma) packed in a glass column. The column was washed with 400 ml of 
distilled water followed by 200 ml of 70% methanol before the active fraction was eluted 
using 200 ml of 95% methanol (adjusted to pH 2) at a flow rate of 15 ml/min. The 
methanol was removed using a rotary evaporator and the resulting peptide was lyophilized 
and stored at -20oC. The lyophilized peptide pellets were dissolved in 20 ml of 20 mM 
sodium phosphate pH 5.8 (binding buffer) Then the sample was injected into fast protein 
liquid chromatography (FPLC) system (ÄKTA Purifier™, Malaysia Genome Institute) 
using SP FF 5ml strong cation exchanger column (GE Healthcare) equilibrated with the 
same buffer at a flow rate of 1 ml/min. Then the column was washed with 10X column 
volume of the binding buffer before BLIS-NU10 was eluted using linear gradient of 0 to 
1M NaCl in 20 mM sodium phosphate buffer at pH 5.8 (Figure 4.32). All bound and 
unbound fractions were tested for inhibitory activity using Micrococcus luteus GAB13 as 
the indicator microorganism.  
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Table 3.4: Column and buffers used in cation exchange study. 
Column* Buffer A Buffer B 
SP FF  
(5 ml) 
20 mM sodium phosphate PH 5.8 
20 mM sodium phosphate PH 5.8 
+ 1 M NaCl 
*HiTrap SP FF is prepacked with SP Sepharose Fast Flow and is a strong cation exchanger.  
 
 
3.13 Tris-Tricine SDS PAGE  
 
The active fractions eluted from the FPLC system were subjected to 16.5% sodium dodecyl 
sulphate (SDS) as described previously (Schagger, 2006) and Tris-Tricine running buffer 
system. Mini-Protean Tetra Cell (Bio Rad) was used according to the manufacturer’s 
instructions. Dual Xtra protein marker (Bio Rad) was used to estimate the molecular weight 
of the pure BLIS-NU10. The gel was run at 125 V for 45 min and stained using 
SimplyBlue™ SafeStain (Life Technologies-Invitrogen). After de-staining, the gel was 
visualized and the molecular weight was estimated (Figure 4.34). 
 
3.14 Activity assay of the purified BLIS-NU10 peptide 
 
The samples were subjected to two-fold serial dilutions and 20µl samples were spotted onto 
the surface of CAB freshly seeded with Micrococcus luteus ATCC® 10240. After 
incubation at 37oC for 18 hours, zones of inhibition were observed and the arbitrary units of 
the inhibitor peptide per ml were measured. The arbitrary unit (AU) is the reciprocal of the 
highest dilution of the pure peptide that showed clear inhibition of Micrococcus luteus 
growth (Mantovani and Russell, 2008) as shown in Figure 4.25. 
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3.15 Characterization of BLIS-NU10 peptides 
 
The pure FPLC fraction was subjected to nano liquid chromatography electrospray 
ionization mass spectrometry LC/MS-ESI analysis. The sample was injected into a 
Symmetry C18 pre-column (5 µm, 20 mm x 180 µm) attached to BEH C18 reversed phase 
analytical column (1.7 µm, 20 cm x 75 µm) using nano ACQUITY@ UPLC system at the 
Malaysia Genome Institute located in Bangi, Malaysia. Elution was carried out with solvent 
A (0.1 formic acid in water) and solvent B (0.1 formic acid in acetonitrile) with a gradient 
of 4-45% of solvent B in solvent A at a flow rate of 3 µl /min for 70 min. The eluted 
peptide molecules were subjected directly to positive electrospray ionization. Q-TOF 
premier system and Protein Lynx Global SERVER V 2.4 software (Malaysia Genome 
Institute) were used to search for peptide spectra. Data directed analysis (DDA) was used 
for de novo amino acids sequencing. For further analysis pure BLIS-NU10 was analyzed by 
matrix-assisted laser desorption ionization - time of flight (MALDI-TOF) mass 
spectrometry (MS) at the Medical Biotechnology Laboratory, Faculty of Medicine, 
University of Malaya (Figure 4.35 and 4.36). 
 
 
 
  
43 
 
3.16 Mode of action bacteriostatic, bactericidal and bacteriolytic  
 
One ml of purified peptide was added to 10 ml of log-phase culture of the indicator strain 
(Micrococcus luteus ATCC) grown in THB. The optical density was measured at 620 nm at 
various times to check if there is any bacterial growth in the bacteriocin-containing culture. 
One ml of distilled water was added to the sensitive culture as a negative control. If the 
indicator bacteria succeeded in growing after sometime, it means the mode of action of the 
inhibitor is bacteriostatic but if it fails then it is bactericidal as shown in figure 4.27. 
Growth kinetics of the indicator bacteria was recorded and analyzed by Microsoft Excel 
software. The bactericidal effect of pure BLIS-NU10 was studied at different phases of 
growth as shown in figure 4.28 where salivaricin was added to freshly inoculated culture 
after 10, 15, 30, 60, 120 and 210 minutes at 37oC and the bacterial growth was recorded by 
measuring OD600.   
 
3.17 Membrane permeabilization assay 
 
Indicator bacteria Micrococcus luteus ATCC 10240, Streptococcus equisimilis 
ATCC12388 and Corynebacterium spp GH17 were subcultured on CAB (Columbia agar 
base). One colony was used to inoculate 1 ml of THB (Todd Hewitt broth) and incubated at 
32oC aerobically for 18 hours at 150 rpm. 1 ml of test strain culture was used to inoculate 
10 ml of THB and incubated with the same conditions mentioned above. The culture was 
grown to an OD600nm value of 0.6 (exponential growing phase). Then the bacterial CFU was 
enumerated using Miles and Misra method (surface viable count) (Heritage et al., 1996). At 
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OD600nm = 0.6 the CFU count was 3.4 X 105. The bacterial culture was centrifuged at 2,000 
x g for 15 minutes, after which the supernatant was discarded. Bacterial pellets were 
washed with 10mm sodium phosphate buffer at pH 7.2 and centrifuged at 2,000 x g for 15 
minutes. This washing step was performed twice. Pellet was suspended with 10 ml of 10 
mM sodium phosphate sterile buffer pH 7.2.  The bacteria was diluted again to reach OD600 
= 0.6 in sodium phosphate buffer. Final volume was made up to 10 ml. 5 µl-1 of SYTOX 
stock solution was added to 5 ml of bacterial preparation mentioned above. 10 µl of peptide 
solution to be tested at different concentrations was added to 90 µl of the (bacteria cells + 
SYTOX) preparation in 96-Well Real Time PCR Plate. Positive control (acidic methanol 
extract from S.salivarius K12 and 70% ethanol) was also added to the same bacterial 
preparation. For negative control bacterial cells without addition of any peptide or positive 
control was used. Each experiment was performed in triplicate. The wells were sealed by 
using optical cap strips and the plate was placed as soon as possible in the Real-Time PCR. 
The real-time PCR (Applied Biosystems StepOnePlus™Real-Time PCR Systems) was 
programmed with SYBR Green filter selected and 60 cycles of 1 min duration at 37oC read 
at the end of each cycle. Raw data was exported into Excel. Results were expressed as 
fluorescence units (FU). Each sample was tested in triplicate. Mean values and standard 
deviation were calculated using Microsoft Excel. 
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3.18 Scanning electron microscopy (SEM) 
 
SEM was used to visualize the mechanism of antimicrobial action of BLIS NU10. Indicator 
bacteria Micrococcus luteus ATCC 10240 was grown in THB for 10 hours till it reached 
the exponential phase with CFU count of 1.2 x 106. The cells were then centrifuged at 8000 
x g for 5 minutes and washed with 20 mM HEPES buffer pH 7 (washing step was repeated 
twice). Cells were centrifuged again at 9000 x g for 2 minutes, supernatant was discarded 
and bacterial pellet was resuspended in 1 ml of purified BLIS NU10 containing 8 AU/ml. 
The samples were fixed with 8% glutaraldehyde in 1:1 (v/v) Sorensen’s phosphate buffer 
for one hour. Samples were then  washed with Sorensen’s phosphate buffer and water 
mixture 1:1 (v/v) before the samples were fixed with 4% OsO4 mixed with 1:1 (v/v) H2O 
and then left  overnight. After washing with deionized water for 15 minutes, the samples 
were dehydrated in increasing concentrations of ethanol as follows: 10%, 20%, 30%, 40%, 
50%, 60%, 70%, 80%, 90% and 100%. Dehydration with ethanol-acetone mixture was 
applied before the samples were finally washed with pure acetone as the last step of 
preparation before critical point drying (CPD). After the samples were prepared and coated 
with gold particles the mechanism of antimicrobial action was visualized using JEOL JSM-
7001F Scanning Electron Microscope. Control sample (without BLIS NU10 treatment) and 
treated sample were then compared for morphological changes. 
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3.19 Stability tests on BLIS-NU10 
 
Heat stability of pure salivaricin was studied by treating the peptide at different 
temperatures for one hour following which the sample was centrifuged and the supernatant 
was tested for inhibitory activity. The stability of the peptide at different pH values was 
also evaluated and tested similarly. For enzymatic effects on salivaricin stability, two wells 
of 6mm diameter each separated by a distance of 4 mm were prepared in a CAB plate. One 
well was filled with 50µl of the pure salivaricin while the other was filled with 50µl of the 
enzyme (1 mg/ml). The plate was incubated at 50oC for 2 hours and then at 37oC overnight 
before the indicator strain was seeded onto the agar surface using a cotton swab. Then the 
plate was re-incubated at 37oC for 18 hours and the zones of inhibition that appeared 
indicated the stability of salivaricin, while absence of inhibition zones indicated the 
denaturation of the antimicrobial peptide by the applied enzymes namely proteinase K, 
peptidase, lyticase and catalase The stability of BLIS-NU10 to the chemicals namely 
EDTA, SDS, urea, NaCl and β-merchaptoethanol was examined by adding 1% of the 
chemicals to the bacteriocin followed by incubation for two hours at RT before the samples 
were centrifuged and the supernatant was tested as described above. If the chemical was a 
solvent e.g. β-mercaptoethanol, the solvent was evaporated before testing for antimicrobial 
activity (Table 4.11). 
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4.1 Streptococcus salivarius isolation and identification 
 
All the strains were isolated from the oral cavities of Malaysian subjects. Some of them 
were isolated from the dorsal surface of the tongue while the others from the saliva. It 
appeared that all isolates were negative for both catalase and oxidase tests with gram 
positive characteristics when viewed under the light microscope after gram staining Figure 
(4.1-4.4).  
 
 
 
 
Figure 4.1: Gram staining of Streptococcus salivarius NU10 
 
 
 
 
 
 
Figure 4.2: Gram staining of Streptococcus salivarius YU10 
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Figure 4.3: Gram staining of Streptococcus salivarius K12 
 
 
 
 
 
Figure 4.4: Gram staining of Streptococcus salivarius GT2 
 
Table 4.1 summarizes the basic characteristics of the isolates with results from the 
simultaneous antagonism assay to evaluate the ability of these strains for producing 
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antimicrobial agents.  Strains NU10 and YU10 were most significant for inhibitory activity 
as shown in figure 4.13 where a large halo zone can be observed surrounding the spot 
where the producer was stabbed. Strain GT2 also showed some activity, but it appeared as a 
smaller halo zone. Further study showed that the inhibitory activity of this strain can be 
extracted using the acidic methanol extraction method of the GT2 cells. All the isolated 
colonies appear blue dome-shaped when grown on MSA plate. Some of the strains 
appeared to have rough colony morphology like strain GT2 which adhered strongly to the 
surface of the agar. This was challenging, especially when the deffered antagonism test was 
applied because the macroscopic growth (visible to the naked eye) of the producer strain 
needed to be scraped off the agar surface before indicator bacteria were applied by 
swabbing. Other colonies of the strains in the study appeared smooth. All the isolates 
appeared to have a dome shape on MSA and this puffy gum shape is due to the production 
of levan as levansucrase enzyme was also detected from the methanol extract of the 
producer’s cells. Some modification on the manufacturer’s protocol was applied to isolate 
the total DNA by adding 100 mg/ml of lysozyme with overnight incubation at 37oC 
increased the yield of DNA recovered significantly. The thick cell wall of S. salivarius 
makes it difficult to lyse in the presence of lysozyme for a short period of incubation (30 
min). But the cell lysis was enhanced significantly with overnight incubation in lysozyme. 
The 16s rDNA gene sequences of the isolates were assembled using DNA baser software. 
After that, the data was blasted on the human oral microbiome database www.homd.org. 
All strains scored ≥99% on the database. 16S rDNA gene identification finally confirmed 
the identity of the isolates. 
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Table 4.1: The basic characteristics of Streptococcus salivarius isolates  
S. salivarius 
isolate 
Gram 
Stain 
Shape 
Catalase 
Test 
Oxidase 
Test 
Isolation 
source 
Antagonism activity* 
Micrococcus 
luteus 
Corynebacterium 
Spp 
NU10 Positive Cocci - - Tongue + + 
YU10 Positive Cocci - - Tongue + + 
7YE Positive Cocci - - Saliva - - 
GT2 Positive Cocci - - Tongue ± - 
HJEFF Positive Cocci - - Tongue - - 
IND9 Positive Cocci - - Saliva - - 
SAM3 Positive Cocci - - Saliva - - 
* Simultaneous antagonism test on BACa plates. 
16s rDNA gene sequencing identification scores according to BLAST tool used in human 
oral microbiome database are listed in Table 4.3. The NCBI data base was used to confirm 
the identity of the isolates. All the isolates showed to be S. salivarius. Finally the 16s rDNA 
gene sequences of all the isolates were deposited in NCBI gene bank. 
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API tests were used to determine the metabolic profile of the strains as shown in Table 4.2. 
Strains NU10 and YU10 differ from strain K12. While K12 was able to metabolize D-
galactose, both strains NU10 and YU10 were negative to this biochemical test. Both strains 
K12 and YU10 were able to metabolize D-tagatose while strain NU10 showed otherwise. 
Inulin metabolism was positive for both strains K12 and NU10 while this test was negative 
when strain YU10 was used. However, strain YU10 metabolized both D-sorbitol and 
GENtiobios, but both strains K12 and NU10 did not metabolize these substrates. Strain 
NU10 was the only strain that showed positive reaction when incubated with AMYgdaline.  
The entire biochemical test for all the strains showed a similar result when API 20 Strep 
was used as they are listed in Table 4.2. The main reason for conducting the API 
biochemical tests was to identify the metabolic profile of strains NU10 and YU10 as they 
showed the best production pattern and it was useful to compare their metabolic pattern 
with that of strain K12 the commercial probiotic which can produce both salivaricin A2 and 
salivaricin B. 
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Table 4.2: Metabolic profile of S. salivarius isolates using API 20 Strep and API 50 CH. 
API 20 Strep K12 NU10 YU10 
Acetoin production + + + 
β-Glucosidase + + + 
Pyrrolidonyl arylamidase    
6-Bromo-2-naphthyl _-D-
galactopyranoside 
- - - 
Naphthol AS-BI_-D-
glucuronate 
- - - 
D- galactosidase - - - 
Alkaline phosphatase + + + 
Leucine arylamidase + + + 
Arginine dihydrolase - - - 
Ribose - - - 
L-Arabinose - - - 
Mannitol - - - 
Sorbitol - - - 
D-Lactose + - + 
    
Trehalose + + + 
Inulin + + - 
Raffinose + + + 
Starch (2) - - - 
Glycogen - - - 
    
API 50 CH    
D-Galactose + - - 
D-Glucose + + + 
D-Fructose + + + 
D-Mannose + + + 
N-Acetylglucosamine + + + 
Arbutine + + - 
Salicin + + + 
D-Cellobiose + + + 
D-Maltose + + + 
D-Lactose + - + 
D-Saccharose + + + 
D-Trehalose + + + 
Inulin + + - 
D-Rafﬁnose + + + 
D-Tagatose + - + 
AMYgdaline - + - 
D-Sorbitol - - + 
GENtiobios - - + 
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Several of the S. salivarius isolates were observed by transmission electron microscopy 
(TEM) to determine the size of the bacteria and details of the bacterial cell morphology. 
TEM pictures showed that the chain-forming bacteria are surrounded by capsular material. 
 
Figure 4.5: TEM section of Streptococcus salivarius NU10. 
The width of each S. salivarius cell was recorded as ≤ 400 nm for bacterial cells in the log 
phase of growth. 
56 
 
Figure 4.6: TEM section of Streptococcus salivarius YU10. 
No flagella was detected in all isolates of S. salivarius since this bacteria is not motile. 
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Figure 4.7: TEM section of Streptococcus salivarius HJEFF 
Sometimes S. salivarius can be shown as single cocci depending on the plane of the 
section. 
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Figure 4.8: TEM section of Streptococcus salivarius 7YE  
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Figure 4.9: TEM section of Streptococcus salivarius GT2 
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Figure 4.10: The genome DNA extracted from Streptococcus salivarius isolates. A, B and 
D: DNA extracted from S. salivarius strains K12, NU10 and YU10 respectively after cells 
lysis for overnight in presence of 100 mg/ml of lysozyme. C and E: DNA extracted from S. 
salivarius strains NU10 and YU10 respectively after incubation with lysozyme was for 
only 30 min. incubating the cells with lysozyme for overnight enhance the yield of DNA 
recovered significantly. 
  
A B C D E 
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Figure 4.11: Gel electrophoresis of 16S rDNA gene sequencing of Streptococcus salivarius 
strains YU10 and NU10 isolated from Malaysian subjects. The PCR product showed a 
single band of amplified gene. The PCR product was purified and sequenced before the 
results were blasted on www.homd.org. 
 
 
Table 4.3: 16s rDNA gene sequencing identification 
Strain Significant alignment Score E value Identities 
NU10 Streptococcus salivarius 2109 0.0 99.9 
YU10 Streptococcus salivarius 2118 0.0 99.9 
7YE Streptococcus salivarius 2198 0.0 99.9 
GT2 Streptococcus salivarius 2176 0.0 99.9 
HJEFF Streptococcus salivarius 2210 0.0 99.9 
IND9 Streptococcus salivarius 2111 0.0 99.9 
SAM3 Streptococcus salivarius 2204 0.0 99.9 
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 Figure 4.12: MS/MS spectrum evidence for VGTLAFLGATQVKA (Levansucrase 
enzyme) produced by Streptococcus salivarius YU1-0 
 
 Levansucrase was detected in the acidic methanol extract of the YU10 cells. The bacteria 
were grown into M17SUCa medium and the extract showed to have antimicrobial activity 
against selected indicators. The detection of cell-bound levansucrase enzyme at a 
significant quantity indicates that this enzyme is a major product of strain YU10 when 
sucrose was used as the only sugar source in the production medium since the detection 
method was developed to detect the most intensive peak. On solid medium levansucrase 
usually polymerizes fructose moiety of sucrose into fructans which possess either inulin or 
levan and this will resulted in a dome-shape colony morphology of the S. salivarius when it 
is grown on MSA (sucrose-enriched selective medium).  
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4.2 Simultaneous antagonism test 
 
Simultaneous antagonism test was used initially to screen for bacteriocin-producing S. 
salivarius strains. Some of the S. salivarius stabbed into BACa medium were able to 
produce antimicrobial activity (Figures 4.13 and 4.14). In this assay a sensitive bacteria like 
Micrococcus luteus was used against which K12, YU10 and NU10 produced the largest 
inhibition zones. HJEFF and GT2 also produced inhibition zones but the activity was faint 
indicating perhaps inhibition due to acidic metabolites.  
 
Figure 4.13: Simultaneous antagonism test of Streptococcus salivarius isolates. A, the test 
was done using Micrococcus luteus as an indicator strain. B, the test was done using 
Corynebacterium spp as indicator strain. The S. salivarius strains were stabbed into a fresh 
lawn of indicator strain seeded on BACa agar. Strains K12, NU10 and YU10 were the best 
producers. 
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Figure 4.14: Simultaneous antagonism test for strains NU10 and K12. A: NU10 was 
stabbed as producer, B: K12 was stabbed as producer. Strain NU10 showed similar activity 
when compared with strain K12. The production of the bacteriocins was on BACa. The 
edges of the inhibition zones caused by antimicrobial activity produced by strain K12 are 
relatively sharp compared with that of strain NU10 and this may be due to the production of 
multiple bacteriocins by strain K12. Micrococcus luteus ATCC 10240 was used as 
indicator. 
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4.3 Deferred antagonism test 
 
For the deferred antagonism assay, two different kinds of production media were used.  Of 
these, TSYECa medium seemed to be good especially for strains HJEFF, 7YE, GT2 and 
SAM3. However, it must be noted that the production appeared inconsistent and inhibition 
was not shown always with the strains from the unhealthy subjects from the Dental Clinic. 
But the strains from the healthy Malaysian subjects showed relatively stable production of 
inhibitory activity. Although the inhibitory activity was not so strong, some strains like 
HJEFF, 7YE and GT2 could also inhibit the growth of Bacillus cereus. Haemophilus 
parainfluenzae was also inhibited by HJEFF and 7YE. After supplying the media with 
0.4% of calcium carbonate, the inhibitory activity was reduced. BACa medium is a 
routinely used medium for this test and it gave a better bacteriocin production especially 
with strains YU10, NU10 and K12.  
One of the reasons for absence of inhibitory activity against some of the indicator bacteria 
when using BACa in deferred antagonism assays is that the inhibitory activity seen when 
using TSYECa might be due to lactic acid produced by the S. salivarius. S. salivarius strain 
HJEFF in later experiments produced minimum inhibition of Bacillus cereus in liquid 
media and the inhibitor was recovered by ammonium sulphate precipitation which proved 
the presence of an inhibitor(s) of protein or peptide constitution produced by HJEFF strain. 
Strains GT2 and K12 were the only producers that caused inhibition of Streptococcus 
mutans in deferred antagonism tests on BACa.   
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Figure 4.15: Deferred antagonism test on BACa agar plates. (Left) K12 was used as 
producer strain. (Right) NU10 was used as a producer strain. Indicator bacteria from top to 
bottom: Micrococcus luteus ATCC 10240, Streptococcus gordonii ST2, Streptococcus 
pyogenes ATCC 12344, Corynebacterium spp GHG17, Streptococcus equisimilis ATCC 
12388 and Lactococcus lactis ATCC 11454.  
 
 
The inhibition characteristic of strain NU10 isolated from a Malaysian subject is similar to 
strain K12. At other times when the deferred antagonism test was repeated, the zones of 
inhibition were more or less. The reason for this fluctuation in production is still unknown. 
However, when Streptococcus pyogenes ATCC 12344 was diluted to OD600 of 0.2 before 
using it as indicator in this test, a significant inhibition zone was observed. 
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Figure 4.16: Deferred antagonism test on TSYECa agar plates. A: BLIS-negative reference 
strain ATCC13419. B: producer strain K12. Indicator bacteria from top to bottom: 
Lactococcus lactis, Bacillus cereus, Corynebacterium spp, Haemophilus parainfluenza, 
Streptococcus mutans, Staphylococcus aureus, Gemella sanguinis, Micrococcus luteus. 
Strain ATCC13419 could not inhibit any of the indicator strains while K12 secreted BLIS 
which inhibited four of the indicator strains used. Table 4.4 summarizes the production 
pattern of all S. salivarius isolates using BACa and TSYECa plates in deferred antagonism 
test.  
 
A B 
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Table 4.4: Deferred antagonism test to evaluate BLIS production by Streptococcus salivarius isolates using two different production media. 
Indicator strain 
Deferred antagonism test using two different type of production media (TSYECa and BACa) 
HJEFF 7YE SAM3 GT2 NU10 YU10 IND9 K12™ 
TSY
ECa BACa 
TSY
ECa BACa 
TSY
ECa BACa 
TSY
ECa BACa 
TSY
ECa BACa 
TSY
ECa BACa 
TSY
ECa BACa 
TSY
ECa BACa 
Bacillus cereus ++ - ++ - - - + - - - + - - - - - 
Haemophilu 
sparainfluenza ++ - ++ - - - + - - - - - - - - - 
Lactococcus lactis - - - - - - - - - + - ++ - - +++ +++ 
Corynebacterium spp +++ + +++ + ++ + +++ ++ +++ +++ +++ +++ - - +++ +++ 
Streptococcus mutans - - - - - - ++ ++ - - - - - - +++ +++ 
Staphylococcus aureus - - - - - - + - - - - - - - ++ ++ 
Streptococcus equisimilis 
 
- 
 
- 
 
- - - +++ +++ +++ +++ - - +++ +++ 
Actinomyces naeslundii - - - - - - - - - - - - - - - - 
Micrococcus luteus + + + + + + 
 
+ +++ +++ +++ +++ - - +++ +++ 
Streptococcus gordonii - - - - - - - - - - - - - - - - 
Streptococcus pyogenes - - - - - - - - + + + + - - ++ +++ 
+ inhibition zone < 0.75 cm, ++ inhibition zone = 0.75 - 1 cm, +++ inhibition zone > 1 cm, - no inhibition
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4.4 Production of BLIS activity in liquid media 
 
All the isolates failed to produce antimicrobial activity while growing in liquid medium. 
Strain HJEFF was able to grow in Muller Hinton broth and the concentrated cell free 
supernatant showed some inhibitory activity. The production of this activity was not stable 
where only small quantity of inhibitory activity could be recovered. When the same 
experiment was repeated no inhibitory activity was recovered. 
Table 4.5: production of BLIS activity using different production methods 
S.salivarius 
strain 
 
Production of 
BLIS in liquid 
media 
Production of BLIS by 
freeze thaw extraction 
 
Production of BLIS by 
methanol extraction of 
producer cells 
NU10 - + + 
YU10 - + + 
7YE - - + 
GT2 - + + 
HJEFF +α - + 
IND9 - - - 
SAM3 - - + 
K12™ - + + 
ATCC13419 - - - 
α Very small quantity of inhibitory activity could be recovered from the concentrated supernatant of this strain 
 
The growth curve of strain HJEFF was studied and the BLIS activity was recovered from 
the late log phase and early stationary phase. Because no activity could be detected directly 
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from the cell free supernatant, ammonium sulphate was added to the supernatant at a 
saturation of 50% to concentrate the activity. 
 
Figure 4.17: Growth curve of strain HJEFF that produce minimum inhibitory activity in 
liquid medium. 
 
 
The bacteria reached the stationary phase after 14 hours of incubation in Mueller Hinton 
broth. The antimicrobial activity test from the supernatant did not detect any inhibitory 
activity during the production. The ammonium sulphate precipitation of cell free 
supernatant harvested from the late log phase and early stationary phase revealed inhibitory 
activity especially against Bacillus cereus. When the production experiment was repeated 
using other media like M17 or THB no activity could be recovered neither from the 
supernatant nor from the ammonium sulphate precipitate. In this case, maybe MH broth 
which has less nutrients comparing with M17 and THB played a role in making the 
bacterial environment more stressful. The inhibitory activity in the ammonium sulphate 
precipitate was purified using DEAE anion exchanger. The inhibitory agent was able to 
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bind to the column and eluted out using 1M NaCl. No activity could be recovered from the 
unbound fractions while three fractions eluted once 1M NaCl was applied showed 
antimicrobial activity against Corynebacterium spp.  
Figure 4.18: Binding of inhibitory activity produced by strain HJEFF in liquid medium to 
the anion exchanger DEAE column. The activity was eluted using 1M NaCl and the 
fractions were tested against Corynebacterium spp. Fractions 1-6 bounded to the DEAE 
column and eluted after washing the column with high salt buffer. The protein was detected 
at wavelength of 280 nm. 
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 Figure 4.19: well diffusion assay of the BLIS activity extracted from cell-free supernatant 
of S.salivarius HJEFF grown in liquid medium after the ammonium sulphate precipitation. 
50µl of the crude inhibitory activity dissolved in distilled water was loaded in each well 
previously cut in CAB plate. After incubation at 37oC for 18 hours clear zones of inhibition 
surrounding the well was measured. Each test was done in triplicate and the standard 
deviation was calculated using Microsoft Office Excel. 
 
 
4.5 Isolation of antimicrobial peptides using acidic methanol extraction 
 
This method has been use for long time to isolate lantibiotics from lactic acid bacteria 
especially in the medical industry were this method can give relatively pure peptide with 
strong activity. In this project the cell-associated peptide was eluted from the cells surfaces 
using 95% methanol pH 2. To enhance the quantity recovered, the producer bacterial strain 
was grown in 2 liters bioreactor and the production media was supplemented with 0.1% 
calcium carbonate which worked as a buffer to reduce the changing in pH condition of the 
culture. Since the peptide was recovered from the cells surfaces it was very important to 
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reduce the acidity of the culture by supplying it with calcium carbonate. If the media got 
more and more acidic, the peptide will start to be eluted out from the bacterial surface into 
the supernatant (desorption), but when the media condition during bacterial growth was 
maintained between pH of 4-6, the extra cellular metabolite (in this case antimicrobial 
peptide) will adsorbed to the surface of the producer strain (adsorption). This method was 
ideal in peptide recovering and the peptides isolated using this method was reasonably pure 
peptide comparing with that recovered by freeze thaw method. From the figure 4.20 we can 
see that the most sensitive indicator bacteria for peptide preparations using acidic methanol 
extraction are Corynebacterium spp and Micrococcus luteus. This support the results 
achieved from deferred antagonism test, where these strains were the most sensitive for the 
producers and this is evidence that the same peptide secreted into agar and cause strong 
inhibition for both sensitive indicators during deferred antagonism assay is the same 
produced and isolated with acidic methanol extraction method.  Peptide extracted by this 
method achieved 64 AU.ml-1 against Corynebacterium spp and 128 AU.ml-1 against 
Micrococcus luteus when S. salivarius NU10 was used as producer strain while S. 
salivarius YU10 gave a titer of 32 AU.ml-1 and 64 AU.ml-1 against Corynebacterium spp 
and Micrococcus luteus respectively. 
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 Figure 4.20: Well diffusion assay of BLIS extracted from different S. salivarius strains by using acidic methanol extraction of the cells.
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Corynebacterium seemed to be one of the most sensitive strains to the acidic methanol 
extraction, while Lactococcus lactis and Bacillus cereus showed some resistance to extracts 
from strains GT2 and NU10.  
Gemella sanguinis and Actinomyces naslundii were not inhibited by the acidic methanol 
extracts of all S. salivarius strains. While Streptococcus mutans was sensitive to extracts 
from strains K12, YU10 and GT2. 
Both strains Micrococcus luteus ATCC10240 and Streptococcus equisimilis were inhibited 
strongly by all acidic methanol extracts especially those extracted from the cell surfaces of 
strains K12 and NU10. Concentrated BLIS extracted from strains K12, NU10, YU10 and 
GT2 inhibited Streptococcus pyogenes. 
  
4.6 Production of BLIS NU10 by freeze thaw extraction 
 
This is a standard method to recover salivaricin A and salivaricin B from S. salivarius K12. 
The production media used to produce the inhibitory peptides from strain K12 was 
modified to produce enhanced quantity of the putative peptide from strain NU10. The 
modified media used in this method was M17 broth supplemented with 1% sucrose, 0.1% 
calcium carbonate and 0.7% agarose. The agarose was selected instead of bacteriological 
agar because it was more efficient during freeze thaw extraction. After autoclaving and 
before pouring the media into petri dishes the media was cooled down till 50oC when 4% of 
S. salivarius NU10 was added to the media and mixed by gentle stirring. 1% of crude BLIS 
NU10 was added before pouring. After the agarose was set the plates (approximately 100 
plates) were incubated anaerobically at 35oC for 22 hours. This method enhanced the 
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A 
B C 
D E 
production of the putative peptide after 65% ammonium sulphate precipitation from 8 
AU.ml-1 against Micrococcus luteus to 128 AU.ml-1 against the same bacteria. 
Table 4.6: Well diffusion assay of BLIS produced by freeze thaw extraction. 
Indicator strain 
Inhibitory activity recovered from  S. salivarius strains with freeze 
thaw  extraction 
HJEFF 7YE GT2 K12 NU10 YU10 
Micrococcus luteus - - 9 15 12 11 
Corynebacterium spp - - 8 16 15 15 
Streptococcus 
equisimilis - - - 12 10 10 
Inhibition zones were measured in millimeter. 
 
 
 
 
 
 
 
  
 
Figure 4.21: Well diffusion assay for BLIS preparation achieved by different methods. 
A,B,C are wells filled with BLIS achieved by freeze thaw extraction from strains YU10, 
NU10 and GT2 strains respectively. D is the desalted BLIS recovered from HJEFF strain 
using vivaspin column after ammonium sulphate precipitation. E is the effluent of the 
desalting process.  
77 
 
 4.7 Purification of BLIS-NU10 produced by freeze thaw extraction: 
 
After the crude BLIS NU10 was extracted by freeze thaw extraction 50% ammonium 
sulphate saturation was applied to concentrate the BLIS activity. The resulting crude BLIS 
NU10 was desalted using Sephadex G 25 column. Figure 4.22 shows the elution profile of 
BLIS NU10 from gel filtration column. 
 
Figure 4.22: Gel filtration chromatography of BLIS NU10 using Sephadex G-25. Gel 
filtration using Sephadex G25 column equilibrated with 25 mM phosphate buffer pH 5.8. 5 
ml fractions were collected at a flow rate of 3 ml/min. The protein concentration was 
measured by NanoDrop 2000 (Thermo Scientific) at 280 nm. All the fractions were tested 
by well diffusion assay using Micrococcus luteus ATCC® 10240 as indicator bacteria. 
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Figure 4.23: Well diffusion assay of fractions eluted from Sephadex G-25 column during 
gel filtration process. Antimicrobial activity of the fractions eluted from Sephadex G25 
column using 25mM Phosphate buffer pH 5.8. 5ml fractions were collected at a flow rate 
of 3 ml/min and 50 µl of each fraction was loaded into 6mm well that had been cut into the 
CAB assay agar freshly seeded with Micrococcus luteus ATCC 10240 by using cotton 
swab. The plates were incubated at 37oC for 18 hours and zone of inhibition was noticed as 
an effect of the desalted antimicrobial peptide. 
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 Table 4.7: purification of BLIS NU10 produced by Streptococcus salivarius NU10 
Step 
Volume 
(ml) 
Activity 
(AU/ml) 
Total 
protein 
(mg) 
Total 
activity 
(AU.103) 
Specific 
activity 
(AU/mg) 
Yield 
(%) 
Purification 
(fold) 
Freeze thaw 
culture 
supernatant 
1000 800 10000 800 80 100 1 
Ammonium 
sulphate 
precipitation 
100 3200 4000 320 40 40 1 
SEPHADEX G-25 
gel filtration  30 3200 320 96 300 12 3.75 
Amberlite XAD-2 
chromatography 15 1600 50 24 480 3 6 
Sep-pak C18 8 3200 0.005 25 5 x106 0.032 640 
 
The XAD-2 chromatography and C18 chromatography following gel filtration gave pure 
NU10 peptide as it shown in table 4.7. Following these steps achieved pure NU10 peptide. 
When the freeze thaw culture supernatant was applied directly to XAD-2 column only 
small quantity of peptide was recovered. That is why steps of ammonium sulphate 
precipitation and Gel filtration were applied to concentrate the inhibitory activity before 
loading into XAD-2 column. XAD-2 chromatography was a great technique to remove all 
hydrophobic proteins from the crude peptide. And it was very easy to recover the activity 
using acidic methanol of 95% concentration. Sep-Pak C18 resin was ideal to capture the 
NU10 peptide and fractionate it by applying gradient concentrations of methanol. 
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Figure 4.24: Well diffusion assay of different preparations of BLIS NU10. A: freeze thaw 
crude, B: 65% ammonium sulphate precipitation, C: Amberlite XAD-2, D: gel filtration G-
25, E: Sep-Pak C18 purification. Indicator bacteria: Micrococcus luteus ATCC® 10240.  
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Figure 4.25: Spot on lawn assay of both crude and purified BLIS NU10 isolated from S. 
salivarius NU10. (Left) BLIS NU10 (crude) activity after freeze thaw extraction and 65% 
ammonium sulphate precipitation.(Right) BLIS NU10 (semi pure) activity after freeze thaw 
extraction, 65% ammonium sulphate precipitation, followed by Sephadex G25 XAD-2 
chromatography and C18 Reverse Phase Sep-pack cartridge solid phase extraction. The 
samples were diluted as two fold serial dilution and spotted as 20µl onto the surface of 
CAB freshly seeded with Micrococcus luteus ATCC® 10240. After incubation at 37oC for 
18 hours a zone of inhibition were noticed and the arbitrary units of the inhibitor per ml 
were counted. 
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4.8 Bacteriostatic, bactericidal and bacteriolytic activity 
 
 
Figure 4.26: Bacteriostatic mode of action of BLIS produced by Streptococcus salivarius 
YU10, Micrococcus luteus ATCC10240 was used as a test culture. 
 
Figure 4.27: Bactericidal mode of action of BLIS produced by Streptococcus salivarius 
NU10, Micrococcus luteus ATCC10240 was used as a test culture. 
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Bacteriostatic and bactericidal mode of action of BLIS preparation was studied depending 
on the growth kinetics of the indicator strain after incubation with BLIS extracted from 
strains NU10 and YU10. After incubation with BLIS YU10, Micrococcus luteus 
ATCC10240 was able to grow again after 20 hours of incubation which indicated that the 
mode of action of BLIS YU10 is bacteriostatic rather than bactericidal. BLIS NU10 
showed bactericidal mode of action where Micrococcus luteus ATCC10240 could not grow 
even after incubation with BLIS NU10 for 30 hours.   
 Figure 4.28: Bacteriolytic Effect of salivaricin BLIS-NU10 on growing culture of 
Micrococcus luteus ATCC10240 when added at different phases of growth. BLIS-NU10 
was added to freshly inoculated culture after 10, 15, 30, 60, 120 and 210 minutes at 37oC. 
Bacterial growth without adding salivaricin was designated as control. The bacterial growth 
was recorded by measuring OD600.   
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4.9 Lantibiotic structural genes 
 
 
 
 
 
 
 
Figure 4.29: Distribution of salivaricin A and salivaricin B encoding structural genes in the 
best two positive producers. salA and sboB genes distribution in S. salivarius isolates (A) 
Gel electrophoresis to detect salivaricin B structural gene after PCR reaction. (B) Gel 
electrophoresis to detect salivaricin A structural gene after PCR reaction. K12 (positive 
control) showed a thick bands for salivaricin A and salivaricin B encoding genes detection. 
The gene expression in K12 strain resulted in thick bands. Strain YU10 appeared to be 
positive for salivaricin A gene and strain NU10 was positive for salivaricin B while K12 
was positive for both genes. 
 
 
Table 4.8: Lantibiotic structural genes: 
S. salivarius salA sboB sivA 
NU10 ±† + + 
YU10 + - + 
† Faint band of salA gene was detected in the PCR product of NU10. 
250 bp 
500 bp 
750 bp 
YU10 K12 
250 bp 
500 bp 
750 bp 
NU10 K12 
A B 
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DNA sequencing of the sboB gene encoding salivaricin B production by S. salivarius strain 
NU10:  
GGTGTGAATTTCCTTCAAGAATTGACTCTTGAAGAAATTGACAACGTTCTTGGT
GCTGGTGGTGGAGTAATCCAAACCATTTCACACGAATGTCGCATGAACTCATG
GCAGTTCTTGTTTACTTGTTGCTCTTAATTACGTTCTATAAGCCTAAATTTTAGC
ACGTAATTTGACTTTTAAGAATTTTAAGGGAGATATATTTAAAATAATATCTTC
TAGAAATTCTAATAGTATCACAATCTAACAATGAGAGGTGTCTCTACTCTTGGT
TTTATTCATAGAAATCTTGTTCATCATGAAAATAGGTGGTCAAAATGGAAAATA
CCGAGAAAAATAAATTATTTAACAAATTTACTAGAAATTTTATCCAAACAAACT
TCTCAGAGTATGATATGCAAAACTGTGAGATAGAATTTTTAGAAGATAAAGTTT
TAGATATTTATATGAATACACTAATCCGTTTGATAAACGAAAAAACAAAATAA
GGAATTTAAAGGGCCCAACTTCGGAAGAGCGGTATGAATATTTTA 
The DNA sequence of sboB gene was translated using expasy translate tool 
(http://web.expasy.org/translate/) and shown to have the following amino acid sequencing: 
GVNFLQELTLEEIDNVLGAGGGVIQTISHECRMNSWQFLFTCCS 
When this sequence blasted on http://www.uniprot.org/ the identity was similar to sboB 
gene product. Strain NU10 and K12 were the only isolates harbour sboB gene. However 
salivaricin B lantibiotic was not detected in the purified BLIS-NU10. Surprisingly 
salivaricin B was not detected when pure BLIS-NU10 was subjected to MALDI-TOF 
analysis. 
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DNA sequencing of the sivA gene encoding salivaricin 9 production by S. salivarius strain 
NU10: 
TATATCCATGAGCTCTCCTAGTGAAATAATTTGAATTTTCCATATTTATAGTATA
TCAAAAATATCAAGTAAAATGTAAGCTCACTAAATTCTTTAGGTTTTCTTAAGG
TAAATTTTGACATTTCTTTATCTTGTACTTATAAAATGTAATTGTAGCTAGATAA
AGATGCTTAATATTGATTTAAATTAAAAAAGGAGAAATATCCATGAAATCAAC
AAATAATCAAAGTATCGCAGAAATTGCAGCAGTAAACTCACTACAAGAAGTAA
GTATGGAGGAACTAGACCAAATTATTGGTGCCGGAAACGGAGTGGTTCTTACT
CTTACTCATGAATGTAACCTAGCAACTTGGACAAAAAAACTAAAATGTTGCTA
ATTATTTAACAAGAAAATTTTACTTAAGCATTCAAGTATTTTTATCTGTTACATA
TTAAGTTGTGTTAATTAACTTAATGGACTTAAAAGTTTGGGGTAAAG 
Expassy DNA to protein translation of the sivA gene detected in strain NU10: 
MKSTNNQSIAEIAAVNSLQEVSMEELDQIIGAGNGVVLTLTHECNLATWTKKLKCC 
sivA gene product (salivaricin 9) was the only known lantibiotic to be detected in the 
MALDI-TOF analysis of purified BLIS-NU10. 
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4.10 BLIS-NU10 induction assay 
 
Table 4.9: Induction of inhibitor production by S. salivarius strains NU10, YU10, K12 and 
nisin-producing strain ATCC11454 using crude preparations, purified FPLC-fraction of 
BLIS-NU10 and nisin. 
 
Inhibitor-positive 
preparation tested for 
inducing activity 
Preparation induces inhibitor production in S. 
salivarius strains and nisin-producing strain 
NU10 YU10 K12 ATCC11454 † 
BLIS-NU10 α Yes  Yes  Yes  No  
FPLC fraction BLIS-NU10 β Yes  Yes  No  No  
BLIS-YU10 α Yes  Yes  Yes  No  
BLIS-K12 α Yes  Yes  Yes  No  
Nisin (Sigma) No  No  No  Yes  
α BLIS (bacteriocin-like inhibitory substances) representing the crude extract of each producer strain. 
β FPLC-purified fraction BLIS-NU10 produced by strain NU10. 
† Lactococcus lactis strain (producer of nisin lantibiotic). 
 
BLIS-NU10 shown to be Auto regulated while small amount of the crude peptide was able 
to enhance the production of BLIS-NU10 when it was incubated with the producer strain. 
BLIS-NU10 shown to be auto-regulated and this discovery used to enhance the production 
of the putative peptide. After the cells were incubated with BLIS produced by K12, YU10 
or NU10 the small quantity of BLIS peptide helped to induce BLIS production (Figure 
4.30). Control sample (washed producer cells + BLIS) was not incubated together with the 
BLIS inducer, the inducer was added to the producer cell free supernatant just before 
loading 50µl of the mixture into the well to test for activity. Absence of the inhibitory 
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action in the control well and clear zone of inhibition in the induced well leads to 
conclusion that strains K12, YU10 and NU10 induced BLIS-NU10 production. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.30: well diffusion assay of the induced producer’s strains. A: BLIS NU10; B & C: 
control (supernatant of the producer strain); D: K12 cells + BLIS YU10; E: YU10 cells + 
BLIS K12; F: YU10 cells + BLIS YU10; G: NU10 cells + BLIS K12; H: NU10 cells + 
BLIS NU10. 
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4.11 Production of BLIS-NU10 in liquid medium 
 
To enhance the production of BLIS-NU10 in liquid medium, a new induction assay was 
developed. The induced culture of S. salivarius NU10 showed detectable amount of the 
inhibitory activity. After 8 hours of the final inoculation the production of BLIS-NU10 
started to increase gradually until it reached more than 1200 AU/ml after 16 hours. Once 
the growth kinetics of strain NU10 reached the stationary phase the level of the inhibitory 
activity remained stable and consistent. 
Figure 4.31: growth kinetics of strain NU10 and BLIS-NU10 production. 
  
4.12 Cation exchange Chromatography 
 
BLIS-NU10 shown to be of cation nature for this reason SP FF strong cation exchanger 
was used to purify the bioactive peptide. This is the first report of using cation 
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chromatography to purify BLIS-NU10. BLIS-NU10 could not be detected at 280 nm. That 
is why two additional wavelengths were used to detect the bioactive peptide. This method 
was ideal to get rid of most of contaminant proteins which was washed out of the column 
without any binding to the cation exchange column. Before injecting the sample into the 
FPLC system the column was washed with 20 mM sodium phosphate buffer to equilibrate 
the column before the positively charged peptide bind to the negatively charged column 
resin. BLIS-NU10 started to be eluted when the NaCl concentration of the elution buffer 
reached 23%. Three fractions (1 ml each) showed significant BLIS-NU10 activity when 
tested in spot on lawn assay using Micrococcus luteus as indicator microorganism. BLIS-
NU10 was detected at wavelengths of 214 and 207 nm. The active fractions eluted from the 
column were colorless with no turbidity at all.  Dissolving the sample with the binding 
buffer enhanced the binding process. Sample preparation before cation exchange 
purification also played a great role in enhancing the binding between the inhibitory 
activity and SP column. The sample was desalted on XAD-16 column before pursuing to 
cation exchange chromatography. This cleaning up process was essential to further purify 
step using AKTA purifier FPLC system. From figure 4.32 it can be seen that BLIS-NU10 
could not be detected at 280 nm due to the absence of aromatic amino acids in this 
lantibiotic. In spot on lawn assay only 10µl or 20µl of each fraction was applied on the 
surface of indicator lawn, in this case only 3 fractions showed antimicrobial activity but 
when well diffusion assay was applied whereby 50µl of each sample was loaded into 6mm 
and this test 6 fractions showed antimicrobial activity including the three fractions from the 
spot on lawn assay. 
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Figure 4.32: Cation exchange chromatography of BLIS-NU10 using SP FF 5ml column.
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Figure 4.33: Spot on lawn assay of the active pure fractions eluted from SP FF column. F1, 
F2, and F3: the three active pure fractions of purified BLIS-NU10 using cation exchange 
chromatography. 
 
 
4.13 Tris-Tricine SDS PAGE 
 
SDS page was used to check the purity of the active three fractions of BLIS-NU10. The 
protein standard used was especially for the low molecular weight proteins and all of the 
three fractions showed to have exactly the same molecular weight of approximately 3,000 
Da. Aliquots (50 µl) of the three fractions from the cation exchange FPLC analyzed by 1D-
SDS-PAGE (Figure 4.34). 
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 Lane 1 was loaded with 10µl the protein marker. Lanes 2,3 and 4 were loaded with 15µl of 
each FPLC fraction prepared in sample buffer. Each of the three fractions showed single 
intense band. 
 
 
 
 
 
 
 
 
 
Figure 4.34: SDS-PAGE of cation exchange FPLC active fractions of BLIS produced by 
strain NU10. Lane 1: Dual Xtra protein marker. Lane 2,3 and 4: FPLC  active BLIS-NU10 
fractions. 
94 
 
4.14 Characterization of BLIS-NU10 
 
Pure BLIS-NU10 was subjected to LC/MS-ESI and MALDI-TOF mass spectrometry to 
identify BLIS-NU10. Salivaricin 9 (2560 Da) was detected in the pure BLIS-NU10. Also 2 
intensive peaks (2068 Da and 2082 Da) were detected.  
Figure 4.35: MALDI-TOF MS analysis of active fraction of BLIS-NU10 from FPLC 
fractionation.  
 
 
 
 
 
 
 
 
 
 
Figure 4.36: MALDI-TOF MS analysis of salivaricin 9 (2560 Da) detected in BLIS-NU10 
fraction from FPLC fractionation. 
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 Figure 4.37: LC/MS-ESI TOF analysis of BLIS-NU10. A: pooled active fractions eluted 
from FPLC system. B: single active fraction eluted from FPLC system (with higher 
inhibitory activity). 
 
LC/MS-ESI analysis also detected the most intensive peaks which were detected in 
MALDI-TOF MS analysis with a molecular weight of 2068 and 2082 Da. The De novo 
amino acid sequencing suggested that these two peptides are rich in proline.  
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 Table 4.10: De novo amino acid sequencing of some detected peptides in pure BLIS-NU10 
Peptide detected in pure BLIS-NU10 Amino acids sequencing 
Salivaricin 9 (2560 Da) GNGVVLTLTHECNLATWTKKLKCC 
Peptide 1 (2068 Da) TPPQHGAVQSPLPSPFPPSQ 
Peptide 2 (2082 Da) TPPNGASGALPHGAAPFNPPQS 
 
When de novo sequenced peptides of molecular weights (2082, 2068) was blasted against 
data base of Swiss port, no significant results could be achieved. 
 
4.15 Membrane permeabilization assay 
 
Investigation of the mode of action of antimicrobial peptide was as described by Bourbon 
et al., (2008) with some modifications. 10 mM Phosphate buffer pH 7.2 was ideal to 
suspend the bacterial cells and do the fluorescence assay because it does not contain any 
DNA fragments which might bind to the SYTOX Green stain and enhance the background 
fluorescence. 70% ethanol was used as a positive control as it is known that ethanol can 
penetrate the bacterial membrane by detergent-like mechanism. The fluorescence in the 
70% ethanol microplate well was strong due to fast penetrating and binding between 
SYTOX green and the inner nucleic acid. The other positive control, K12 bacteriocin, was 
extracted from S. salivarius K12 and this extract contains more than two antimicrobial 
peptides since the strain can produce salivaricin A, salivaricin B and others. The SYTOX 
fluorescence was also strong in this well but it was also noticed that the membrane 
penetration started very fast once the K12 extract was added to the bacteria. We can see 
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from Figure 4.38 that BLIS-NU10 isolated from S. salivarius strain NU10 at different 
concentrations had penetrated the cell membrane of Micrococcus luteus ATCC 10240. 
Even 0.00625 g ml-1 of NU10 peptide could penetrate the cell membrane and cause 
permeabilization of the indicator bacteria in which the fluorescence signal for this well was 
significantly higher than the negative control (indicator bacteria without peptide added). 
This negative control well showed low and consistent fluorescence signal. Tetracycline was 
added to the indicator bacteria in the final well to see if any obvious fluorescence could be 
detected after treating the bacteria with 0.1 mg ml-1 of tetracycline and the fluorescence 
was below the negative control and this is evidence that tetracycline did not penetrate the 
cell membrane and no permeabilization action occurred. After the real time PCR run was 
completed, the bacteria was collected from the wells and washed with phosphate buffer and 
then diluted 1:100 with the same buffer and streaked on CAB plates before incubation for 
18 hours. Bacteria collected from negative control wells could grow perfectly while 
bacteria collected from 70% ethanol and tetracycline wells were not able to grow. 
Micrococcus luteus cells treated with tetracycline did not exhibit significant fluorescence 
during Real-Time PCR run and when the tetracycline treated cells were subcultured on 
fresh medium after the Real-Time PCR run was complete, there was no bacterial growth 
indicating that Tetracycline mechanism of action is not membrane permeabilization action 
but protein synthesis inhibition. The Permeabilization assay was repeated using different 
indicator microorganisms to confirm the membrane penetration activity toward targeted 
cells. Figure 4.39 shows the permeabilization activity using Streptococcus equisimilis and 
Corynebacterium spp as indicator strains. 
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Figure 4.38: Permeabilization of Micrococcus luteus ATCC® 10240 membrane by BLIS-
NU10. The bacterial cells suspension was incubated with different concentration of BLIS-
NU10 with 5 µM SYTOX Green. ●, ethanol 70%; ●BLIS-K12; ●BLIS-NU10 0.05 g ml-1; 
● BLIS-NU10 0.025 g ml-1; ●negative control; ● tetracycline 0.1 mg m-1. Binding of 
fluorescent probe to intracellular nucleic acid was determined at 521nm.
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 Figure 4.39: Permeabilization of targeted cell membrane by BLIS-NU10. A: indicator 
strain used Streptococcus equisimilis. B: indicator strain used Corynebacterium spp. 
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Figure 4.40: Well diffusion assay of purified BLIS-NU10 peptide isolated from S. 
salivarius NU10. 50µl of the purified peptide (0.05 g ml-1) added to the wells (6 mm) have 
been cut into CAB media. A: Streptococcus gordonii ST2, B: Micrococcus luteus ATCC 
10240, C: Streptococcus equisimilis ATCC 12388, D: Corynebacterium spp GHG17, E: 
Lactococcus lactis ATCC11454, F: Streptococcus pyogenes ATCC 12344, G: Haemophilus 
parainfluenza TONE J11 and H:   Actinomyces naeslundii TG2. 
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4.16 Scanning Electron Microscopy  
 
Scanning electron microscopy helped to confirm that the mechanism of action was done by 
permeabilization of the cell membrane. Six hours of bacterial incubation time with BLIS-
NU10 was enough to penetrate the cell membrane as shown in figure 4.41 that the bacteria 
was affected by BLIS-NU10 and some pores were formed in the cell membrane causing 
bacterial contents to ooze through the pores as the first step of the peptide penetrating the 
cell membrane. This is a common mechanism of action for lantibiotics. After that the 
bacteria will lose all the inner contents and start to collapse and die. Some cells were badly 
affected by BLIS-NU10 and after the inner material went out through the pores, the cells 
were ruptured.  
 Figure 4.41: SEM sections show the mechanism of action of purified BLIS-NU10 isolated 
from S. salivarius NU10. A: a healthy Micrococcus luteus ATCC 10240 cell without 
treatment used as a control in this experiment. B: release of internal materials through pores 
formed by NU10 peptide. C: a ruptured Micrococcus luteus ATCC 10240 cell after 
incubation with purified NU10 peptide at 37oC for 6 hours. 
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Figure 4.42: SEM sections show the mechanism of action of purified BLIS-NU10 isolated 
from Streptococcus salivarius NU10 using different indicator strains. 
Indicator strain Control (untreated) Treated with BLIS-NU10 
Micrococcus luteus  A B 
Streptococcus equisimilis C D 
Corynebacterium spp E F 
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4.17 BLIS-NU10 stability (thermo-stability/ pH/ proteinase K/ chemicals) 
 
Table 4.11: Stability profile of BLIS-NU10  
Stability  Concentration  Inhibition zone  
Temperature (oC)   
4, 20, 30, 37, 40, 50, 60, 70, 80 
 for 1 hour 
 ++++ 
90, 100 
 for 30 min 
 +++ 
121 for 20 min 
 
 - 
pH value   
2- 7  ++++ 
8-10  +++ 
11-12 
 
 - 
Enzymes 1 mg ml-1  
Proteinase   - 
Proteinase K  - 
Peptidase  - 
Lyticase  ++++ 
Catalase 
 
 ++++ 
Detergents / Chemicals 1% (W/V)  
Tween 80  ++++ 
Tween 20  ++++ 
Tritone X100  ++ 
β-merchaptoethanol  ++++ 
SDS  ++++ 
EDTA  ++++ 
Urea  ++++ 
NaCl  ++++ 
(++++): inhibition zone >20 mm, (+++): inhibition zone =20 mm, (++): inhibition zone < 20 mm, (-): no bacterial inhibition. 
Micrococcus luteus was used as indicator. Salivaricin 9 titer: 800 AU/ml. 
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Figure 4.43: Enzyme stability test of BLIS-NU10. Black arrows indicates where the 
enzymes where loaded close to where BLIS-NU10 was loaded. A: proteinase K, B: 
catalase, C: control and D: lyticase.
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5.1 Streptococcus salivarius isolation  
 
S. salivarius is a predominant coloniser of the oral cavity in humans. Some S. salivarius 
produce small molecules called BLIS to aid their competition within the oral ecosystem 
which comprises of a large number of diverse communities of microorganisms. Most of the 
BLIS molecules produced by S. salivarius are lantibiotics or lanthionine-containing 
peptides. All Malaysian subjects in this study were shown to have S. salivarius in their oral 
cavity. Some of these isolates were swabbed from the tongue of subjects with periodontal 
problems e.g. dental caries, gum disease and halitosis. Two of the S. salivarius isolated 
from these subjects (SAM3 and IND9) failed to produce significant BLIS activity and in 
further investigations in this present study it was found that most of the activity totally 
disappeared when the isolates were grown on medium supplemented with calcium 
carbonate (refer to the data as table or figure from Results). This indicates that their limited 
activity is due to the production of lactic acid. However, some of the S. salivarius isolated 
from healthy Malaysian subjects (NU10 and YU10) showed significant BLIS production, 
especially when blood-containing medium was used in the production study.  
For primary isolation, MSA or M17 supplemented with 20% sucrose media were used 
since S. salivarius colonies appear as dome-shaped puffy colonies when the growth 
medium is supplemented with sucrose. This unique characteristic is due to levan 
production. In further investigation of BLIS-producing isolate YU10, the bacteria were 
shown to produce a significant amount of 103.9 kDa levansucrase enzyme (Figure 4.12) 
when grown in M17 supplemented with 1% sucrose and 0.1 % calcium carbonate. This 
enzyme polymerizes the fructose moiety of sucrose into fructans which possess levan 
structure (Ebisu et al., 1975).  
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5.2 BLIS production by Streptococcus salivarius isolated from Malaysian subjects 
 
S. salivarius strain HJEFF was the only strain that showed some BLIS production when it 
was growing in MHB. No BLIS activity could be detected from the cell free supernatant 
(CFS) but anti-Bacillus cereus and anti-Haemophilus parainfluenzae activity could be 
detected from the ammonium sulphate precipitate of the CFS. Surprisingly no BLIS 
production was evident when more enriched media was used in the production study. In the 
deferred antagonism assay some strains, namely HJEFF, 7YE and GT2, showed a very 
weak BLIS production when BACa was used as a production medium but when TSYECa 
was used instead of BACa the BLIS activity was increased significantly. The production of 
BLIS activity in TSYECa medium and its reduced production in BACa medium was also 
reported in a study of salivaricin M production. Unlike most of the bacteriocins produced 
by S. salivarius, salivaricin M was not produced efficiently in blood-enriched medium and 
there appeared to be strict regulation of its locus expression (Wescombe et al., 2012). 
Salivaricin M produced by S. salivarius strain M18 (BLIS Technologies) is a 
chromosomally encoded lantibiotic (unlike most lantibiotics produced by S. salivarius) 
which is active against Streptococcus mutans. The very first characterized lantibiotic 
produced by S. salivarius strain 20P3 is salivaricin A (2315 Da). Salivaricin A production 
is encoded by salA, located on a megaplasmid. Salivaricin A has 5 variants namely A1, A2, 
A3, A4 and A5 with molecular weights of 2327 Da, 2368 Da, 2319 Da, 2342 Da and 2329 
Da respectively. The mode of action of salivaricin A appeared to be bacteriostatic rather 
than bactericidal. Strain YU10, isolated from a Malaysian subject appeared to have the 
structural gene salA and the antimicrobial activity of the lantibiotic produced by this strain 
was reported in this study. Techniques used to extract the bioactive peptide from this strain 
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were successful when freeze thawed extraction from the agar culture and acidic methanol 
extraction of the centrifuged and isolated cells were applied. No detectable BLIS activity 
could be recovered from this strain when the bacteria were grown in liquid medium. In 
further investigation, strain YU10 appeared to harbour both sivA and slnA (structural genes 
encoding salivaricin 9 and salivaricin G32 respectively) in addition to salA which makes 
strain YU10 a good BLIS producing strain (Tagg, 2013). BLIS produced by strain YU10 
was bacteriostatic in action and this mode of action was similar to that of salivaricin A. 
Strain NU10 was also isolated from one Malaysian subject and showed BLIS production in 
deferred and simultaneous antagonism tests. Out of six isolates, both strains NU10 and 
YU10 showed good BLIS production especially when the deferred antagonism test was 
done on BACa medium and that is linked to the need blood medium to secrete the 
antimicrobial peptide into the agar-supplemented medium. Strain NU10 showed erratic 
BLIS production. When this strain was used as BLIS producer in deferred and 
simultaneous antagonism tests, it secreted BLIS in BACa medium when it was grown in 
both aerobic and anaerobic conditions. It has been noticed that when NU10 was grown in 
anaerobic condition, the BLIS production was increased significantly. Usually BLIS 
production is optimum in CO2-enriched atmosphere, especially when strain K12 is used as 
the BLIS producer (Hyink et al., 2007). When strain NU10 was grown in such a CO2 
enriched condition, it took a longer time than K12 to reach the stationary phase although it 
could still secrete BLIS into the medium. BLIS production in strain NU10 was unstable and 
when glucose or lactose was used instead of sucrose as a carbon source, almost no BLIS 
production could be detected. In an attempt to enhance BLIS production in strain NU10, 
1% of sucrose was added to M17 medium supplemented with 0.1% calcium carbonate 
instead of 0.5% of sucrose as used in past and published procedures to generate BLIS in 
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K12 (Hyink et al., 2007). In this study increasing the sucrose percentage from 0.5% to 1% 
resulted in a more homogenous and turbid bacterial culture increasing the CFU as well.  
 
5.3 BLIS-NU10 purification 
 
Attempts to purify the inhibitory molecules produced by strain NU10 began by first 
concentrating the BLIS activity of the freeze thawed extract by adding solid ammonium 
sulphate. The lowest saturation that precipitated the inhibitory activity was 40%, but to 
recover significant amounts of BLIS, 65% saturated ammonium sulphate was required. 
Ammonium sulphate precipitation was found to be the ideal method to precipitate and 
concentrate BLIS-NU10 based on the current investigations. Gel filtration was applied 
using SEPHADEX G25 column. This combination of ammonium sulphate and gel filtration 
was reported previously for purification of zoocin A produced by Streptococcus 
zooepidemicus strain 4881 and viridin B produced by Streptococcus mitis (Apelgren and 
Dajani, 1979). This preparation of crude BLIS-NU10 was loaded into XAD-2 column to 
get rid of hydrophobic molecules and impurities. XAD-2 was previously used to prepare 
salivaricin A and B from freeze thawed extract of K12 culture (Hyink et al., 2007). Sep-pak 
C18 cartridge increased the purity from 6 to 640 fold which makes this technique effective 
in BLIS-NU10 purification. Sep-pak C18 cartridge was used previously to achieve semi 
purified streptin (type A1 lantibiotic produced by Streptococcus pyogenes strain M25) 
(Wescombe and Tagg, 2003).  
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5.4 BLIS-NU10 and BLIS-YU10 mode of action 
 
Salivaricin A, the first lantibiotic to be characterized from S. salivarius, has no dehydrated 
residues in its biologically active propeptide form and it exhibits bacteriostatic mode of 
action towards the targeted cells rather than bactericidal (Hyink et al., 2007). BLIS-YU10 
appeared to exhibit a bacteriostatic mode of action when the BLIS was added to a log phase 
culture of the indicator microorganism the bacterial growth being inhibited and no increase 
in OD measurement observed. However, after a few hours of incubation the bacteria started 
to grow again in the presence of BLIS-YU10. Purified BLIS-NU10 produced by strain 
NU10 showed a bactericidal mode of action and the indicator microorganism failed to grow 
in the presence of BLIS-NU10 after 30 hours of incubation. BLIS-NU10 was added to 
different phases of targeted bacterial growth and each time BLIS-NU10 effectively reduced 
the OD readings when it was added. Such bacteriolytic activity was reported as a mode of 
action for both bovicin and nisin (de Carvalho et al., 2007) 
 
5.5 Bacteriocin induction activity and BLIS-NU10 production in liquid medium  
 
It has been reported that some bacteriocins including salivaricin A, B (Hyink et al., 2007; 
Ross et al., 1993) and mutacin (Nicolas et al., 2011) are controlled by quorum sensing 
mechanisms and they are better expressed when the producer bacteria is grown on solid 
media where the bacteria can be found in high density. This production strategy will result 
in significant bacteriocin expression in that particular medium comparing with low density 
of bacteria growing in liquid media where no detectable bacteriocin production can be 
observed (Kleerebezem et al., 1997; Qi et al., 2000). Usually to produce these classes of 
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bacteriocins, a freeze thaw method is used while the bacteria are grown on solid or semi-
solid media containing agar or agarose. In this study, a new method was developed to 
produce the bacteriocin in liquid medium. When the production experiment was applied for 
the first time using S. salivarius NU10 as a producer, no inhibitory activity could be 
detected from the cell free supernatant of the culture. Most lantibiotics biosynthesis can be 
auto regulated by signal transduction system like bovicin HJ50 produced by Streptococcus 
bovis (Ni et al., 2011) and salivaricin A produced by S. salivarius 20P3 (Upton et al., 2001) 
and nisin produced by Lactococcus lactis (Kuipers et al., 1995). To investigate in what 
stage of the bacterial growth the optimum quantity of BLIS-NU10 is being produced, a 
liquid medium system was applied to count the CFU followed by the peptide titer. The 
induction procedure showed that BLIS-NU10 is auto-regulated. As the bacteria continues 
to grow in the medium in the presence of the introduced BLIS-NU10 molecules for the 
induction, the expression of BLIS-NU10 in liquid medium was increased significantly by 
1200 AU/mL (Figure 4.31). Feeding the induced culture with fresh medium helped to scale 
up the productivity while the culture itself worked as inoculum and inducer at the same 
time. 
 
5.6 Cation exchange chromatography as BLIS purification strategy 
 
Using cation exchange chromatography to purify lantibiotics has been described previously 
(Furmanek et al., 1999; Sahl, 1994). Salivaricin B purification described previously (Hyink 
et al., 2007) by using XAD-2 chromatography and RPHPLC system has been used to 
separate specific lantibiotics namely salivaricin A2 and B produced by strain S. salivarius 
strain K12. The current study is the first report of BLIS-NU10 purification using SP 
113 
 
sepharose column as a cation exchange technique. Using cation exchange chromatography 
resulted in enhanced yield of BLIS-NU10 which was recovered after XAD-16 
chromatography and preferred over XAD-2 chromatography due to its higher capacity to 
bind the lantibiotic. XAD-2 particles had been used previously to adsorb salivaricin A 
molecule (Ross et al., 1993). Amberlite XAD-4 was used to adsorb nisin molecules 
(Tolonen et al., 2004). XAD-16 hydrophobic resin was a critical step in the current 
protocol to achieve clear and desalted crude peptide. XAD-16 Amberlite was used 
previously to adsorb LtnA1 and LtnA2 that formed the two components of lacticin 3147 
(Morgan et al., 2005). FPLC system showed capability to separate BLIS-NU10 from crude 
preparations achieved from XAD-16 chromatography and this purification protocol 
resulted in single protein intensive band when Tris-Tricine SDS-PAGE was applied. Most 
but not all of the impurities were washed out from the column without any binding to the 
SP Sepharose resin while more than one bound peak was detected after elution with a linear 
gradient of increasing salt concentration. The bioactivity test of all the unbound and bound 
fractions showed that 3 active fractions related to one peak were eluted after applying a 
specific moderate concentration of NaCl ≈ 23%. This finding indicates that BLIS-NU10 is 
of cationic nature. 
 
5.7 Membrane permeabilization and pores forming mechanism of action 
 
Permeabilization activity of lantibiotics toward gram positive bacteria has been studied 
previously (Chun and Hancock, 2000). The depolarization of the cytoplasmic membrane of 
gram positive bacteria was assessed by dequenching of SYTOX green fluorescence by pure 
BLIS-NU10 in this study. Type A lantibiotics (e.g. nisin, salivaricin and epidermin) are 
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amphipathic and elongated molecules which mainly act by forming pores into the 
cytoplasmic membrane of the targeted bacterial cell (Kordel et al., 1989; Moll et al., 1996; 
van Heusden et al., 2002). Lipid II is an initial factor to induce a transmembrane orientation 
of the pore forming lantibiotic (van Heusden et al., 2002). At some stages lantibiotics such 
as nisin can form pores and can inhibit the cell wall biosynthesis when it binds to the 
peptidoglycan precursor lipid II (Wiedemann et al., 2001). Studying the mechanism of 
action of BLIS-NU10 showed the same characteristics compared with other lantibiotics 
while it shares the membrane permeabilization mechanism of action which form pores in 
the cytoplasmic membrane of the sensitive gram positive bacteria as shown in this study in 
the SEM images (Figures 4.41 and 4.42) using targeted bacteria incubated with BLIS-
NU10. The pores formed after incubation with BLIS-NU10 showed variation when the 
three indicator strains were used. After 240 minutes of BLIS-NU10 incubation with 
Micrococcus luteus or Corynebacterium spp, the SEM image in figure 4.42 showed 
significant pores in the targeted cell membrane wherein the bacterial cells were ruptured 
completely resulting in significant changes in cell morphology. However, another sensitive 
strain namely Streptococcus equisimilis showed less susceptibility to BLIS-NU10 
compared to Micrococcus luteus or Corynebacterium spp in deferred antagonism test and 
permeabilization activity assay. The SEM visualized that no significant changes in cell 
morphology occurred in this strain after incubation with BLIS-NU10.  
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5.8 BLIS-NU10 stability 
 
BLIS-NU10 showed heat stability when it was exposed to high temperature (90-100oC). 
BLIS-NU10 remained active for 9 months when it was stored at 4oC. At low temperature 
conditions (-20oC) BLIS-NU10 did not lose any of its activity for 9 months. BLIS-NU10 is 
stable in different values of pH ranging 2-10. However, at extreme alkaline conditions (pH 
11-12) BLIS-NU10 lost most if not all its activity while it was noticed that the optimum pH 
values of BLIS-NU10 stability is pH 2-7 (Table 4.16). However BLIS-NU10 activity 
showed no decreasing in activity after heating at 80oC for 30 min when all available 
indicator strains were tested including Micrococcus luteus, Corynebacterium spp and 
Streptococcus equisimilis. Usually bacteriocins with a molecular weight <5 kDa are heat 
stable molecules including lantibiotics (Nes et al., 2007). When treated with proteinase K 
or peptidase, BLIS-NU10 lost its antimicrobial activity which indicates that BLIS-NU10 is 
of protein nature.  
 
5.9 BLIS-NU10 as a potential probiotic 
 
When strain NU10 was tested as a producer strain in deferred antagonism test using 9 
indicator strains (Tagg and Bannister, 1979) to determine what kind of salivaricin strain 
NU10 can produce, the scheme showed no production characteristics of either salA nor 
salB (Tagg, personal communication). However, strain NU10 showed to harbour the 
structural genes of three different lantibiotics (salA, salB and sal9). This finding indicates 
that although NU10 harbours known structural genes of previously described lantibiotics, 
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the biologically active product of the structural genes mentioned above might not be 
expressed during production studies and the only gene product detected in MALDI-TOF 
MS analysis is salivaricin 9 (Figure 4.36). The mode of action of BLIS-NU10 showed to be 
bactericidal rather than bacteriostatic. Hence we can conclude that BLIS-NU10 is not salA 
(the bacteriostatic lantibiotic) (Wescombe et al., 2006). BLIS-NU10 showed to be auto-
inducible where it enhanced the inhibitory activity production when incubated with the 
washed cells of strain NU10. To enhance BLIS-NU10 production, strain NU10 always 
required to be stimulated by induction assay of the same BLIS molecules. MALDI-TOF 
MS analysis showed the presence of salivaricin 9 (2560 Da) in the current study. However, 
in addition to the salivaricin 9 peak, another 3 intensive peaks were detected, each of 
molecular weight approximately 2000 Da and these peaks showed to be proline-rich 
peptides which is uncommon among salivaricins. When these peptides were de novo 
sequenced, they showed no significant similarity of any previously characterized 
bacteriocins.  
  
117 
 
  
 
 
 
 
 
Chapter Six 
Conclusion  
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S. salivarius strains were isolated from six Malaysian subjects using sucrose-enriched 
media. Sucrose was used in the medium as S. salivarius metabolize sucrose into levan by 
levansucrase enzyme which was detected in the cultures of S. salivarius grown in such a 
medium. The isolates were identified using API kits and 16S rDNA gene sequencing for 
further confirmation. All these isolated strains 16S rDNA genomic sequences were 
deposited in the NCBI database. Some of the isolates appeared to produce bacteriocin-like 
inhibitory activity when tested in both simultaneous and deferred antagonism tests. An 
attempt was applied to produce the inhibitory activity in liquid media. However, strain 
HJEFF was the only strain that produced limited inhibitory activity when grown in MHB. 
The ammonium sulphate precipitate of the cell free supernatant of strain HJEFF was of 
anionic nature inhibiting Bacillus cereus and Haemophilus parainfluenzae.  Strains K12, 
NU10 and YU10 showed significant inhibition against Micrococcus luteus, 
Corynebacterium spp, Streptococcus equisimilis and Lactococcus lactis. Antimicrobial 
crude peptide was obtained from strains K12, NU10 and YU10 using acidic methanolic 
extraction of the producer cells and freeze thaw extraction of the strains using M17SUCa 
medium. BLIS produced by strain YU10 was bacteriostatic in its mode of action while 
BLIS obtained from strain NU10 was bactericidal. The distribution of structural genes 
encoding previously characterized salivaricins was investigated in the Malaysian isolates. 
Strain YU10 harboured salA, sivA and slnA encoding salivaricin A, salivaricin 9 and 
salivaricin G32 respectively. Hence strain YU10 has good potential for application as a 
probiotic. Strains K12 and NU10 harboured sboB (a structural gene encoding salivaricin B) 
and sivA encoding salivaricin 9. When strain NU10 was applied in deferred antagonism 
assay using 9 standard indicators, it appeared that the inhibitory activity produced by NU10 
was not from either salivaricin A or salivaricin B. A new method was used to enhance 
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BLIS-NU10 production in liquid medium. BLIS-NU10 was shown to be auto-regulated. 
Cation exchange chromatography was used to purify BLIS-NU10 and the pure fractions 
were subjected to Tris-Tricine SDS PAGE to demonstrate the molecular weight, which 
appeared to be about 3,000 Da. Further analysis of the purified BLIS-NU10 using MALDI-
TOF MS showed the presence of salivaricin 9 lantibiotic (2560 Da). Other peptides with 
molecular weights of 2068 Da and 2082 Da detected in BLIS-NU10. When these peptide 
sequences where blasted against SwissProt and NCBI databases, no significant matches 
were found. The BLIS-NU10 mechanism of action was studied using SYTOX green dye to 
investigate the ability of BLIS-NU10 to penetrate the cytoplasmic membrane of the 
targeted cells. BLIS-NU10 induced cytoplasmic membrane permeabilization of its targeted 
bacteria. Scanning Electron Microscope images of sensitive bacteria treated with BLIS-
NU10 showed that the antimicrobial peptide induces pore formation in the indicator 
bacterial membrane. BLIS-NU10 exhibited thermo-stability when exposed to a temperature 
of 100oC for 30 minutes and retained biological activity when subjected to different pH 
values ranging from 2 to 10. When treated with proteinase K, BLIS-NU10 lost all of its 
antimicrobial activity. BLIS-NU10 can be a potentially new antimicrobial peptide, but 
further work may be needed to detect the structural genes encoding BLIS-NU10 
production. 
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APPENDIX A 
26th April 2012 
 
Volunteer information sheet 
Re: Study of bacteriocins produced by Streptococcus salivarius isolated from 
Malaysian subjects 
Dear volunteer, 
We would like to invite you to take part in a research study. In this study, we wish 
to obtain information about the bacteriocins produced by Streptococcus salivarius isolated 
from Malaysian subject.  
As part of the research, your oral samples will be collected in the morning (9-10 
am) before consuming any food. Please refrain from oral hygiene measures on the sampling 
day. You can have teeth brushed on the previous day as usual but brushing and mouth rinse 
solution should be avoided on the day of sampling. Your oral samples will be collected 
from the tongue surface by cotton swabs. The sampling procedure is a painless and non-
invasive process. 
Taking part in this research will not benefit you directly and is entirely voluntary. If 
you have any questions about the research, please do not hesitate to ask. 
 
Thank you. 
 
………………….. 
Abdelahhad Barbour 
M.S.c Candidate 
Microbiology Division 
Institute of Biological Sciences 
Faculty of Science 
University of Malaya 
Kuala Lumpur 
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APPENDIX B 
Consent form 
 
Re: Study of bacteriocins produced by Streptococcus salivarius isolated from 
Malaysian subjects 
 
1. I have read the volunteer information sheet 
2. I have had the opportunity to ask questions and discuss the research 
3. I am satisfied with the answers to the questions 
4. I have received enough information about the research 
5. I agree to take part in this research 
 
 
 
Signature of volunteer: ………………………………….. 
 
Name   :…………………………………… 
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APPENDIX C 
Details of subjects included in this study:  
S. salivarius 
isolate 
Gender Age Race Smoker* 
Dental 
problems 
Isolation 
source 
NU10 Female 25 Malay No No Tongue 
YU10 Female 25 Chinese No No Tongue 
GT2 Female 25 Chinese No No Tongue 
7YE Male 7 Malay No Yes Saliva 
IND9 Female 26 Indian No Yes Saliva 
SAM3 Female 35 Indian No Yes Saliva 
HJEFF Male 26 Malay No No Tongue 
*Only exclusion criterion used was to exclude smokers  
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 APPENDIX D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Deferred antagonism assay using different S. salivarius strains. The producer strains were 
grown aerobically. Indicators used from top to bottom: Micrococcus luteus, Haemophilus 
parainfluenzae, Bacillus cereus, Lactococcus lactis, Corynebacterium spp, Streptococcus 
Pyogenes, Staphylococcus aureus, Streptococcus equisimilis, Streptococcus mutans and 
Streptococcus gordonii. When strain K12 was grown aerobically with 5% CO2, an 
increment in the inhibitory activity was observed specially against Streptococcus 
equisimilis and Streptococcus mutans. 
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Deferred antagonism assay using TSYECa as a production medium.  
  
  
  
  
Deferred antagonism test using 7YE and HJEFF strains as producers. TSYE 
medium was used with or without calcium carbonate supplement. 
Corynebacterium spp was used as an indicator in replicates. 
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Freeze thaw extraction using M17SUCa as a production medium. The frozen solid culture 
was thawed at a room temperature.  
 
 
Precipitated protein obtained from 60% ammonium sulphate 
precipitation. Solid ammonium sulphate was added to the liquid 
obtained from freeze thaw extraction and centrifuged at 18,000 
x g for 30 min to precipitate the inhibitory activity. 
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Concentrated crude BLIS-NU10 obtained by freeze thaw extraction using two different 
production medium namely M17SUCa and THBCa. When tested by well diffusion assay 
BLIS-NU10 obtained using M7SUCa medium showed positive inhibitory activity when 
tested against Corynebacterium spp. 
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APPENDIX E 
SEM (Morphological changes) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Morphological changes of Streptococcus equisimilis treated with pure BLIS-NU10. White 
arrow indicates the inner bacterial material oozing out through pore formed by BLIS-
NU10.  
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Morphological changes of Streptococcus equisimilis treated with pure BLIS-NU10. 
White arrow indicates the inner bacterial material oozing out through pore formed 
by BLIS-NU10. 
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 Morphological changes of Corynebacterium spp treated with pure BLIS-NU10. White 
arrow indicates the inner bacterial material oozing out through pore formed by BLIS-
NU10.  
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 APPENDIX F 
Streptococcus salivarius isolates in this study deposited to NCBI gene bank: 
 
Streptococcus salivarius strain NU10 16S ribosomal RNA gene, partial sequence 
GenBank: KC796011.1 
LOCUS       KC796011                1358 bp    DNA     linear   BCT 06-APR-2013 
ORIGIN       
1 gctcttcttg gatgagttgc gaacgggtga gtaacgcgta ggtaacctgc cttgtagcgg 
61 gggataacta ttggaaacga tagctaatac cgcataacaa tggatgactc atgtcattta 
121 tttgaaaggg gcaaatgctc cactacaaga tggacctgcg ttgtattagc tagtaggtga 
181 ggtaacggct cacctaggcg acgatacata gccgacctga gagggtgatc ggccacactg 
241 ggactgagac acggcccaga ctcctacggg aggcagcagt agggaatctt cggcaatggg 
301 ggcaaccctg accgagcaac gccgcgtgag tgaagaaggt tttcggatcg taaagctctg 
361 ttgtaagtca agaacgagtg tgagagtgga aagttcacac tgtgacggta gcttaccaga 
421 aagggacggc taactacgtg ccagcagccg cggtaatacg taggtcccga gcgttgtccg 
481 gatttattgg gcgtaaagcg agcgcaggcg gtttgataag tctgaagtta aaggctgtgg 
541 ctcaaccata gttcgctttg gaaactgtca aacttgagtg cagaagggga gagtggaatt 
601 ccatgtgtag cggtgaaatg cgtagatata tggaggaaca ccggtggcga aagcggctct 
661 ctggtctgta actgacgctg aggctcgaaa gcgtggggag cgaacaggat tagataccct 
721 ggtagtccac gccgtaaacg atgagtgcta ggtgttggat cctttccggg attcagtgcc 
781 gcagctaacg cattaagcac tccgcctggg ggagtacgac cgcaaggttg aaactcaaag 
841 gaattgacgg gggcccgcac aagcggtgga gcatgtggtt taattcgaag caacgcgaag 
901 aaccttacca ggtcttgaca tcccgatgct atttctagag atagaaagtt acttcggtac 
961 atcggtgaca ggtggtgcat ggttgtcgtc agctcgtgtc gtgagatgtt gggttaagtc 
1021 ccgcaacgag cgcaacccct attgttagtt gccatcattc agttgggcac tctagcgaga 
1081 ctgccggtaa taaaccggag gaaggtgggg atgacgtcaa atcatcatgc cccttatgac 
1141 ctgggctaca cacgtgctac aatggttggt acaacgagtt gcgagtcggt gacggcaagc 
1201 taatctctta aagccaatct cagttcggat tgtaggctgc aactcgccta catgaagtcg 
1261 gaatcgctag taatcgcgga tcagcacgcc gcggtgaata cgttcccggg ccttgtacac 
1321 accgcccgtc acaccacgag agtttgtaac acccgaag 
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Streptococcus salivarius strain YU10 16S ribosomal RNA gene, partial sequence 
GenBank: KC796012.1 
LOCUS       KC796012                1371 bp    DNA     linear   BCT 06-APR-2013 
ORIGIN       
1 ggtagccgta acttgctctt cttggatgag ttgcgaacgg gtgagtaacg cgtaggtaac 
61 ctgccttgta gcgggggata actattggaa acgatagcta ataccgcata acaatggatg 
121 actcatgtca tttatttgaa aggggcaaat gctccactac aagatggacc tgcgttgtat 
181 tagctagtag gtgaggtaac ggctcaccta ggcgacgata catagccgac ctgagagggt 
241 gatcggccac actgggactg agacacggcc cagactccta cgggaggcag cagtagggaa 
301 tcttcggcaa tgggggcaac cctgaccgag caacgccgcg tgagtgaaga aggttttcgg 
361 atcgtaaagc tctgttgtaa gtcaagaacg agtgtgagag tggaaagttc acactgtgac 
421 ggtagcttac cagaaaggga cggctaacta cgtgccagca gccgcggtaa tacgtaggtc 
481 ccgagcgttg tccggattta ttgggcgtaa agcgagcgca ggcggtttga taagtctgaa 
541 gttaaaggct gtggctcaac catagttcgc tttggaaact gtcaaacttg agtgcagaag 
601 gggagagtgg aattccatgt gtagcggtga aatgcgtaga tatatggagg aacaccggtg 
661 gcgaaagcgg ctctctggtc tgtaactgac gctgaggctc gaaagcgtgg ggagcgaaca 
721 ggattagata ccctggtagt ccacgccgta aacgatgagt gctaggtgtt ggatcctttc 
781 cgggattcag tgccgcagct aacgcattaa gcactccgcc tggggagtac gaccgcaagg 
841 ttgaaactca aaggaattga cgggggcccg cacaagcggt ggagcatgtg gtttaattcg 
901 aagcaacgcg aagaacctta ccaggtcttg acatcccgat gctatttcta gagatagaaa 
961 gttacttcgg tacatcggtg acaggtggtg catggttgtc gtcagctcgt gtcgtgagat 
1021 gttgggttaa gtcccgcaac gagcgcaacc cctattgtta gttgccatca ttcagttggg 
1081 cactctagcg agactgccgg taataaaccg gaggaaggtg gggatgacgt caaatcatca 
1141 tgccccttat gacctgggct acacacgtgc tacaatggtt ggtacaacga gttgcgagtc 
1201 ggtgacggca agctaatctc ttaaagccaa tctcagttcg gattgtaggc tgcaactcgc 
1261 ctacatgaag tcggaatcgc tagtaatcgc ggatcagcac gccgcggtga atacgttccc 
1321 gggccttgta cacaccgccc gtcacaccac gagagtttgt aacacccgaa g 
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Streptococcus salivarius strain Gt2 16S ribosomal RNA gene, partial sequence 
GenBank: KC796010.1 
LOCUS       KC796010                1039 bp    DNA     linear   BCT 06-APR-2013 
ORIGIN       
1 tgaagttgcg gcggctatac atgcaagtag aacgctgaag agaggagctt gctcttcttg 
61 gatgagttgc gaacgggtga gtaacgcgta ggtaacctgc cttgtagcgg gggataacta 
121 ttggaaacga tagctaatac cgcataacaa tggatgacac atgtcattta tttgaaaggg 
181 gcaattgctc cactacaaga tggacctgcg ttgtattagc tagtaggtga ggtaacggct 
241 cacctaggcg acgatacata gccgacctga gagggtgatc ggccacactg ggactgagac 
301 acggcccaga ctcctacggg aggcagcagt agggaatctt cggcaatggg ggcaaccctg 
361 accgagcaac gccgcgtgag tgaagaaggt tttcggatcg taaagctctg ttgtaagtca 
421 agaacgagtg tgagagtgga aagttcacac tgtgacggta gcttaccaga aagggacggc 
481 taactacgtg ccagcagccg cggtaatacg taggtcccga gcgttgtccg gatttattgg 
541 gcgtaaagcg agcgcaggcg gtttgataag tctgaagtta aaggctgtgg ctcaaccata 
601 gttcgctttg gaaactgtca aacttgagtg cagaagggga gagtggaatt ccatgtgtag 
661 cggtgaaatg cgtagatata tggaggaaca ccggtggcga aagcggctct ctggtctgta 
721 actgacgctg aggctcgaaa gcgtggggag cgaacaggat tagataccct ggtagtccac 
781 gccgtaaacg atgagtgcta ggtgttggat cctttccggg attcagtgcc gcagctaacg 
841 cattaagcac tccgcctggg gagtacgacc gcaaggttga aactcaaagg aattgacggg 
901 ggcccgcaca agcggtggag catgtggttt aattcgaagc aacgcgagaa ccttaccagg 
961 tcttgacatc ccgatgctat ttctagagat agaaagttac ttcggtacat cggtgacagg 
1021 tggtgcatgg ttgtcgtca 
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Streptococcus salivarius strain 7YE 16S ribosomal RNA gene, partial sequence 
GenBank: KC796009.1 
LOCUS       KC796009                1025 bp    DNA     linear   BCT 06-APR-2013 
ORIGIN       
1 cgtggggggg gtgctaatac atgcaagtag aacgctgaag agaggagctt gctcttcttg 
61 gatgagttgc gaacgggtga gtaacgcgta ggtaacctgc cttgtagcgg gggataacta 
121 ttggaaacga tagctaatac cgcataacaa tggatgactc atgtcattta tttgaaaggg 
181 gcaattgctc cactacaaga tggacctgcg ttgtattagc tagtaggtga ggtaacggct 
241 cacctaggcg acgatacata gccgacctga gagggtgatc ggccacactg ggactgagac 
301 acggcccaga ctcctacggg aggcagcagt agggaatctt cggcaatggg ggcaaccctg 
361 accgagcaac gccgcgtgag tgaagaaggt tttcggatcg taaagctctg ttgtaagtca 
421 agaacgagtg tgagagtgga aagttcacac tgtgacggta gcttaccaga aagggacggc 
481 taactacgtg ccagcagccg cggtaatacg taggtcccga gcgttgtccg gatttattgg 
541 gcgtaaagcg agcgcaggcg gtttgataag tctgaagtta aaggctgtgg ctcaaccata 
601 gttcgctttg gaaactgtca aacttgagtg cagaagggga gagtggaatt ccatgtgtag 
661 cggtgaaatg cgtagatata tggaggaaca ccggtggcga aagcggctct ctggtctgta 
721 actgacgctg aggctcgaaa gcgtggggag cgaacaggat tagataccct ggtagtccac 
781 gccgtaaacg atgagtgcta ggtgttggat cctttccggg attcagtgcc gcagctaacg 
841 cattaagcac tccgcctggg gagtacgacc gcaagtgttg aaactcaaag gaattgacgg 
901 gggcccgcac aagcggtgga gcatgtggtt taattcgaag caacgcgaag aaccttacca 
961 ggtctgacat cccgatgcta tttctagaga tagaaagtta cttcggtaca tcggtgacag 
1021 tgttg 
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Streptococcus salivarius strain SAM3 16S ribosomal RNA gene, partial sequence 
GenBank: KC796008.1 
LOCUS       KC796008                1021 bp    DNA     linear   BCT 06-APR-2013 
ORIGIN       
1 ggaagggcgg gtgctataca tgcaagtaga acgctgaaga gaggagcttg ctcttcttgg 
61 atgagttgcg aacgggtgag taacgcgtag gtaacctgcc ttgtagcggg ggataactat 
121 tggaaacgat agctaatacc gcataacaat ggatgactca tgtcatttat ttgaaagggg 
181 caattgctcc actacaagat ggacctgcgt tgtattagct agtaggtgag gtaacggctc 
241 acctaggcga cgatacatag ccgacctgag agggtgatcg gccacactgg gactgagaca 
301 cggcccagac tcctacggga ggcagcagta gggaatcttc ggcaatgggg gcaaccctga 
361 ccgagcaacg ccgcgtgagt gaagaaggtt ttcggatcgt aaagctctgt tgtaagtcaa 
421 gaacgagtgt gagagtggaa agttcacact gtgacggtag cttaccagaa agggacggct 
481 aactacgtgc cagcagccgc ggtaatacgt aggtcccgag cgttgtccgg atttattggg 
541 cgtaaagcga gcgcaggcgg tttgataagt ctgaagttaa aggctgtggc tcaaccatag 
601 ttcgctttgg aaactgtcaa acttgagtgc agaaggggag agtggaattc catgtgtagc 
661 ggtgaaatgc gtagatatat ggaggaacac cggtggcgaa agcggctctc tggtctgtaa 
721 ctgacgctga ggctcgaaag cgtggggagc gaacaggatt agataccctg gtagtccacg 
781 ccgtaaacga tgagtgctag gtgttggatc ctttccggga ttcagtgccg cagctaacgc 
841 attaagcact ccgcctgggg agtacgaccg caaggttgaa actcaaagga attgacgggg 
901 gcccgcacaa gcggtggagc atgtggttta attcgaagca acgcgaagaa ccttaccagg 
961 tcttgacatc ccgatgctat ttctagagat agaaagttac ttcggtacat cggtgacagt 
1021 g 
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APPENDIX G 
 
De novo amino acid sequencing of the major peaks detected in pure BLIS-NU10. A: 2068.0376Da; B: 2084.00
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